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A B S T R A C T
Background
This review is an update of a previously published review in the Cochrane Database of Systematic Reviews, 2005, Issue 4 (and last
updated in the Cochrane Database of Systematic Reviews, 2013 issue 8), on local anaesthetic blockade (LASB) of the sympathetic
chain to treat people with complex regional pain syndrome (CRPS).
Objectives
To assess the efficacy of LASB for the treatment of pain in CRPS and to evaluate the incidence of adverse effects of the procedure.
Search methods
For this update we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (2015, Issue 9), MEDLINE (Ovid),
EMBASE (Ovid), LILACS (Birme), conference abstracts of the World Congresses of the International Association for the Study of
Pain, and various clinical trial registers up to September 2015. We also searched bibliographies from retrieved articles for additional
studies.
Selection criteria
We considered randomised controlled trials (RCTs) that evaluated the effect of sympathetic blockade with local anaesthetics in children
or adults with CRPS compared to placebo, no treatment, or alternative treatments.
Data collection and analysis
We used standard methodological procedures expected by Cochrane. The outcomes of interest were reduction in pain intensity, the
proportion who achieved moderate or substantial pain relief, the duration of pain relief, and the presence of adverse effects in each
treatment arm. We assessed the evidence using GRADE (Grading of Recommendations Assessment, Development and Evaluation)
and created a ’Summary of findings’ table.
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Main results
We included an additional four studies (N = 154) in this update. For this update, we excluded studies that did not follow up patients
for more than 48 hours. As a result, we excluded four studies from the previous review in this update. Overall we included 12 studies
(N = 461), all of which we judged to be at high or unclear risk of bias. Overall, the quality of evidence was low to very low, downgraded
due to limitations, inconsistency, imprecision, indirectness, or a combination of these.
Two small studies compared LASB to placebo/sham (N = 32). They did not demonstrate significant short-term benefit for LASB for
pain intensity (moderate quality evidence).
One small study (N = 36) at high risk of bias compared thoracic sympathetic block with corticosteroid and local anaesthetic versus
injection of the same agents into the subcutaneous space, reporting statistically significant and clinically important differences in pain
intensity at one-year follow-up but not at short term follow-up (very low quality evidence).
Of two studies that investigated LASB as an addition to rehabilitation treatment, the only study that reported pain outcomes demon-
strated no additional benefit from LASB (very low quality evidence).
Eight small randomised studies compared sympathetic blockade to various other active interventions. Most studies found no difference
in pain outcomes between sympathetic block versus other active treatments (low to very low quality evidence).
One small study compared ultrasound-guided LASB with non-guided LASB and found no clinically important difference in pain
outcomes (very low quality evidence).
Six studies reported adverse events, all with minor effects reported.
Authors’ conclusions
This update’s results are similar to the previous versions of this systematic review, and the main conclusions are unchanged. There
remains a scarcity of published evidence and a lack of high quality evidence to support or refute the use of local anaesthetic sympathetic
blockade for CRPS. From the existing evidence, it is not possible to draw firm conclusions regarding the efficacy or safety of this
intervention, but the limited data available do not suggest that LASB is effective for reducing pain in CRPS.
P L A I N L A N G U A G E S U M M A R Y
Local anaesthetic sympathetic blockade for complex regional pain syndrome
Background
Local anaesthetic sympathetic blockade (LASB) is a common treatment for complex regional pain syndrome (CRPS). It involves
blocking the activity of sympathetic nerves alongside the spine. The sympathetic nervous system mainly controls unconscious actions
such as heart rate, blood flow, and perspiration. The injection of a local anaesthetic drug around the nerves temporarily blocks the
function of the nerves. This updated review aimed to summarise the available evidence regarding whether LASB is effective at reducing
pain in CRPS, how long any pain relief might last, and whether LASB is safe.
Key results and quality of the evidence
In September 2015, we found a limited number of small trials, all of which had design flaws. We did not find evidence that LASB was
better than placebo in reducing pain, or that it provided additional pain relief when added to rehabilitation. While a number of small
studies compared LASB to other treatments, most did not find that LASB was better. One small study found that injecting the thoracic
(upper back) sympathetic nerves with local anaesthetic and steroid was better than injecting the same drugs just under the skin at one-
year follow-up, but the study may have been prone to bias. Only six studies reported on the type and amount of side effects. These
studies reported only minor side effects, but since some studies did not report this information we can draw no firm conclusions about
the safety of LASB. The evidence was mostly of low or very low quality.
Overall, the evidence is limited, conflicting, and of low quality. While we cannot draw strong conclusions, the existing evidence is not
encouraging.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Patient or population: adults with CRPS
Setting: secondary care
Intervention/ comparison: LASB vs various comparisons
Outcome: pain intensity 0-10 (VAS or NRS)






Quality of the evidence
(GRADE)
LASB vs placebo Aydemir 2006; Price
1998




LASB + steroid vs sub-
cutaneous local anaes-
thet ic+ steroid
Rocha 2014 36 (1) Favours LASB
Mean dif ference (0-10
scale)
One month −1.25 (95%
CI −3.2 to 0.7)





Aydemir 2006 18 (1) No signif icant between-
group dif ference
⊕⊕©© Lowc
LASB vs IVRB guanethi-
dine
Bonelli 1983 19 (1) No signif icant between-
group dif ference
⊕©©© Very lowb
LASB lumbar plexus vs
pulsed radiof requency
lumbar plexus
Freitas 2013 40 (1) No signif icant between-
group dif ference
⊕©©© Very lowb
LASB (lidocaine + cloni-
dine) vs IVRB (lidocaine
+ clonidine)
Nascimento 2010 43 (1) No signif icant between-
group dif ference
⊕©©© Very lowb
LASB + PT+ pharmaco-
logical vs PT + pharma-
cological
Rodriguez 2005 82 (1) Favours SGB group ⊕©©© Very lowb




vs cont inuous brachial
plexus block
Toshniwal 2012 33 (1) Favours brachial plexus
block
⊕⊕©© Lowc
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Image-guided LASB vs
nonimage-guided LASB
Yoo 2012 42 (1) Mean dif ference
2 weeks post inject ion
−0.58 (95%CI −1.51 to
0.35)
4 weeks post inject ion
−0.74 (95%CI −1.36 to
−0.12)
©©©© Very lowd
Outcome: hand pain 0-3 scale
LASB vs oral cort icos-
teroids
Lim 2007 38 (1) 15 day follow-up,no sig-
nif icant between-group
dif ference at
30 day follow-up 0.4
(95% CI −0.69 to −0.
11), favours LASB with
steroid
©©©© Very lowd
Outcome: duration of pain relief
LASB bupivacaine +
BTA vs LASB bupiva-
caine
Carroll 2009 9 (1) Increased durat ion of
relief with BTA
Median t ime to anal-
gesic failure (days):
LASB bupivacaine +
BTA 71 (95% CI 12 to
253)
LASB bupivacaine 10
(95%CI 0 to 12)
⊕⊕©© Lowc
a Downgraded once for imprecision.
b Downgraded three t imes for lim itat ions, inconsistency, and imprecision.
cDowngraded twice for inconsistency and imprecision.
dDowngraded four t imes for lim itat ions, inconsistency, indirectness, and imprecision.
B A C K G R O U N D
This review is an update of a previously published review in the
Cochrane Database of Systematic Reviews, 2005, Issue 4 (and last
updated in the Cochrane Database of Systematic Reviews, 2013
Issue 8), on local anaesthetic sympathetic blockade for complex
regional pain syndrome.
Description of the condition
Complex regional pain syndrome (CRPS) is an umbrella term for
a variety of clinical presentations characterised by chronic persis-
tent pain that is disproportionate to any preceding injury (if any)
and that is not restricted anatomically to the distribution of a spe-
cific peripheral nerve (Bruehl 2010). The International Associa-
tion for the Study of Pain (IASP) introduced the diagnostic label
of CRPS in the 1990s (Merskey 1994), and since then, others have
updated it in an attempt to improve its specificity (Harden 2006;
Harden 2010). We present these modified diagnostic criteria (the
’Budapest criteria’) in Table 1. The term CRPS encompasses a va-
riety of earlier diagnostic terms, including reflex sympathetic dys-
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trophy (RSD), reflex neurovascular dystrophy, Sudeck’s atrophy,
causalgia, and algodystrophy/algoneurodystrophy (Stanton-Hicks
1995). CRPS can be classified into two subtypes: CRPS-I, in which
there is no identified peripheral nerve injury, and CRPS-II, where
symptoms are associated with a definable nerve lesion (Harden
2006). This distinction is not always easily made (Harden 2006).
Both subtypes of CRPS are characterised by severe pain that is
disproportionate to the inciting event, most commonly affect-
ing the hand or foot but sometimes spreading to other body re-
gions (Stanton-Hicks 2002; Van Rijn 2011). Additionally CRPS
presents with some or all of the following symptoms in the affected
body parts: sensory disturbances; temperature changes; abnormal
patterns of perspiration; swelling/oedema; reduced joint range of
motion; movement abnormalities such as weakness, tremor, or
dystonia; trophic changes such as skin atrophy, altered hair and nail
growth, or localised osteoporotic changes (Bruehl 2010; De Mos
2009; Shipton 2009); and alterations in body perception (Lewis
2007; Lotze 2007; Moseley 2006). CRPS occurs most commonly
following wrist fracture and subsequent immobilisation. However,
cases can potentially occur after relatively minor trauma and may
even occur spontaneously, albeit rarely (De Mos 2007; De Mos
2008; Sandroni 2003). The underlying pathophysiological mech-
anisms of CRPS are incompletely understood, although there is
growing consensus that it is primarily a disorder of the nervous
system. Research has identified abnormalities in the tissues of the
affected area and the peripheral and central nervous systems (Jänig
2003; Marinus 2011). These include signs of increased neurogenic
inflammation (Birklein 2001; Schinkel 2006; Schmelz 2001), an
altered local immune response (Birklein 2014; Tan 2005), altered
activity in the sympathetic nervous system (SNS) (Drummond
2004; Niehof 2006), increased sensitivity to normal SNS activ-
ity (Albrecht 2006; Ali 2000; Drummond 2001), and local tissue
hypoxia (Birklein 2000; Koban 2003). Studies have also demon-
strated changes in the brain in CRPS (Swart 2009), including al-
terations of the cortical (higher brain) representation of the af-
fected body part (Maihöfner 2004; Pleger 2006), localised reduc-
tions in grey matter density and connectivity (Geha 2008), and
altered inhibitory control (Schwenkreis 2003).
Description of the intervention
Sympathetic blockade includes procedures that aim to temporarily
impede the local function of the sympathetic nervous system. Usu-
ally an anaesthesiologist performs the procedure, injecting local
anaesthetic directly into sympathetic neural structures that serve
the affected limb(s) such as the stellate ganglion or the lumbar
sympathetic chain (Nelson 2006). Radiologic guidance such as
fluoroscopy or computerised tomography (CT) scan often ensures
the accuracy of needle tip placement, and successful blockade is
often monitored by direct (e.g., galvanic skin response) or indirect
(increase in blood flow to the extremity or increase in tempera-
ture) assessment (Breivik 2009). This approach is distinct from
the injection of neurolytic agents in an effort to destroy sympa-
thetic nerves. LASBs are also commonly called stellate ganglion
blockades (SGB) or, when performed in the lower body, lumbar
sympathetic blockades (LSB).
How the intervention might work
People with persistent pain following nerve injury have long been
observed to have abnormalities of autonomic nervous system func-
tion in the affected limb (temperature, blood flow, sweating) and
abnormal skin texture or hair and nail growth attributed, at least
in part, to local autonomic dysfunction (Bruehl 2010; De Mos
2009). Early uncontrolled observations of persistent improvement
in signs and symptoms following local anaesthetic sympathetic
blockade in people with what is now termed CRPS suggested that
excessive sympathetic activity provoked or perpetuated this type
of persistent pain (Campbell 1996). However, recent evidence re-
garding adrenaline content in venous effluents from affected limbs
has not supported this hypothesis and suggests instead that any
benefit of sympathetic blockade in CRPS may reflect transient re-
versal of a heightened local sensitivity to adrenaline (Binder 2009).
These clinical impressions of persistent benefit from transient local
anaesthetic sympathetic blockade in CRPS, reinforced by similar
longstanding impressions of prolonged benefit after temporary lo-
cal anaesthetics blockade in peripheral neuralgias, led to the incor-
poration of sympathetic block into current consensus treatment
algorithms for CRPS (Carr 2011), although doubt remains over
the contribution of the sympathetic nervous system to pain and
the concept of sympathetically maintained pain in CRPS (Harden
2013).
Why it is important to do this review
Despite preclinical evidence that suggests the sympathetic ner-
vous system is involved in the pathophysiology of CRPS, there
is debate surrounding the contribution of the sympathetic ner-
vous system to the clinical syndrome (Ochoa 1995; Schott 1995;
Verdugo 1994a; Verdugo 1994b). The value of blocking the sym-
pathetic nervous system is also disputed (Fine 1994; Hogan 1997;
Jadad 1995; Verdugo 1994a). It is therefore important to evaluate
the efficacy of sympathetic blockade with local anaesthetic in the
treatment of CRPS. A meta-analysis of the effect of sympathetic
blockade with local anaesthetics in people with CRPS reported
that up to 44% of those subjected to sympathetic blockade would
be expected to have no pain relief. Due to the lack of randomised
controlled trials, investigators obtained this estimate from pooling
the results of observational studies (Cepeda 2002). Moreover, the
review only evaluated English-language studies, and it could have
overlooked relevant RCTs. Hence, to overcome this limitation, we
decided to perform a systematic review of the literature with no
language restriction to determine both the efficacy and safety of
5Local anaesthetic sympathetic blockade for complex regional pain syndrome (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
sympathetic blockade with local anaesthetics to alleviate pain in
people with CRPS.
O B J E C T I V E S
To assess the efficacy of LASB for the treatment of pain in CRPS
and to evaluate the incidence of adverse effects of the procedure.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered randomised controlled trials (RCTs). As blinding
of sympathetic block is not always possible, we included trials
that were either double-blind, single-blind, or open. We included
studies that compared LASB with placebo interventions, no treat-
ment, or alternative interventions. We also included studies that
investigated the effect of adding LASB to other interventions.
Types of participants
We included studies that evaluated the effect of sympathetic block-
ade with local anaesthetics to treat CRPS in children or adults. We
included studies even if the authors did not describe the constel-
lation of symptoms necessary to diagnose CRPS and stated only
that “patients with RSD/CRPS were included”. We took this ap-
proach to avoid excluding any of the relatively few RCTs of this
intervention. We placed no restrictions regarding the number of
participants recruited to trials.
We excluded trials that evaluated sympathetic blockade for other
pain syndromes such as radiculopathy, herpes zoster, postherpetic
neuralgia, fibromyalgia, or phantom pain.
Types of interventions
We included studies that evaluated selective sympathetic block-
ade with local anaesthetics. We excluded studies that only evalu-
ated somatic nerve blocks or studies that evaluated the effect of
local anaesthetics or sympatholytic drugs administered orally, in-
travenously, or epidurally. We excluded studies that reported the
results of combined sympatholytic therapies, such as surgical sym-
pathectomy or guanethidine intravenous regional block plus local
anaesthetic blockade of the sympathetic chain. We also excluded
studies of ganglionide local opioid analgesia (GLOA), a technique
in which clinicians locally inject opioids such as buprenorphine
into the stellate ganglion, because this procedure does not block
sympathetic activity.
Types of outcome measures
The outcomes of interest were pain intensity levels, duration of
pain relief. and adverse events. For this update, we excluded studies
that had only immediate follow-up data (≤ 48 h), because this
information provides little clinically relevant information about
the effectiveness of this treatment. We applied this new criterion to
studies that had been included in previous updates of this review.
Search methods for identification of studies
For this update, we used identical search strategies to that of our
2013 review update. For the search strategies, see Appendix 1
for the Cochrane Central Register of Controlled Trials (CEN-
TRAL), Appendix 2 for MEDLINE, Appendix 3 for EMBASE,
and Appendix 4 for LILACS.
We performed the search for the original review from November
2003 to January 2004 updated it on 17 November 2011 and 22
November 2012 (2013 update). The present update encompasses
searches run from 22 November 2012 to 16 September 2015.
We evaluated non-English language papers for inclusion.
For the 2016 update, we did not search the Cochrane Pain, Pal-
liative and Supportive Care Group Specialised Register, as it is no
longer updated.
Electronic searches
We searched the following databases for the update of this review.
• CENTRAL (The Cochrane Library 2015, Issue 9).
• MEDLINE (Ovid) (1966 to September 2015).
• EMBASE (Ovid) (1974 to September 2015).
• LILACS (Birme) (1982 to September 2015).
Searching other resources
Reference lists
We searched the bibliographies of retrieved articles for additional
studies.
Unpublished studies
In order to minimise the impact of publication bias, we reviewed
conference abstracts of the World Congresses of the International
Association for the Study of Pain from 1995 up to 2014. For
this update, we expanded the search of the original review by
also searching relevant clinical trial registers (from inception) for
upcoming trials. We searched the following clinical trial registers:
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the controlled trials register (15 October 2015; www.controlled-
trials.com/), the United States National Institute of Health service
ClinicalTrials.gov (15 October 2015; www.clinicaltrials.gov/); the
Australian New Zealand Clinical trials register (15 October 2015;
www.anzctr.org.au/), and the European Clinical Trials Register (7
December 2012; www.clinicaltrialsregister.eu/).
Personal contact
We attempted to communicate with authors if we needed addi-
tional information that was not provided in the trial report. In
addition, we provided the reference list of included studies to ex-
perts in the field to determine if any additional references were
appropriate for the review.
Data collection and analysis
Selection of studies
Two review authors independently read each of the titles and ab-
stracts of the reports identified by the search and discarded nar-
rative reviews, case series, and case reports. If there was no ab-
stract, we retrieved the full-text report. If there was disagreement,
the authors met to reach consensus, consulting an independent
third review author if necessary. We retrieved in full all abstracts
and reports that made reference to a trial of sympathetic blockade
with local anaesthetics . Two review authors then independently
assessed the full-text articles. We did not anonymise the reports
for the assessment.
Data extraction and management
Two review authors independently extracted the data. If there was
disagreement, they met to reach consensus, consulting an inde-
pendent third review author if necessary. We extracted the follow-
ing data from each study.
1. Study details: study design (parallel or cross-over), method
of randomisation, presence or absence of blinding.
2. Demographic characteristics: age, sex, number of
participants recruited, number of study withdrawals or drop-
outs, if any.
3. Participant clinical characteristics: duration of pain before
sympathetic block, site of pain (arm, leg, mixed, or other such as
facial).
4. Type of noxious initiating event (if known): surgery,
fracture, crush injury, projectile, or stab injury.
5. Type of tissue injured: nerve, soft tissue, bone.
6. Presence of medico-legal factors that may influence the
experience of pain and the outcomes of therapeutic interventions.
7. Concomitant treatments that may affect outcome:
antidepressants, physical therapy, etc.
8. Treatment characteristics: site of sympathetic block (cervical
or lumbar), type of local anaesthetic used (including
concentration and volume), evaluation of the technical adequacy
of the block, duration of follow-up, duration of the pain relief,
number of blocks performed, method of pain assessment, and
presence of complications or adverse effects.
9. Information on postprocedure analgesic requirements.
10. Information on conflicts of interest and statements of study
support.
If authors reported pain intensity using a visual analogue scale or
numeric rating scale, we extracted the mean and standard deviation
of pain intensity in each study arm. If authors reported pain relief,
we extracted the proportion of participants in each category of
pain relief.
Assessment of risk of bias in included studies
We used a modified version of the Cochrane ’Risk of bias’ tool
with additional domains added in response to the recommenda-
tions of Moore 2010. On this basis we added two domains, ’size’
and ’duration’, using the thresholds for judgement suggested by
Moore 2010. We have not added the ’outcome’ domain as this is
covered already by our choice of primary outcome measures. Thus
in addition to the standard items in the ’Risk of bias’ tool:
• selection bias (random sequence generation, allocation
concealment);
• performance bias (blinding of participants and personnel);
• detection bias (blinding of outcome assessment);
• attrition bias (incomplete outcome data; consideration of
analysis methods, e.g., imputation method);
• reporting bias (selective reporting); and
• other sources of bias;
We also assessed the following domains as recommended by Moore
2010.
• Size (rating studies with fewer than 50 participants per arm
as being at high risk of bias, those with between 50 and 199
participants per arm as being at unclear risk of bias, and 200 or
more participants per arm as being at low risk of bias).
• Duration (rating studies with follow-up of two weeks as
being at high risk of bias, two to seven weeks as being at unclear
risk of bias and eight weeks or longer as being at low risk of bias).
Two review authors completed the ’Risk of bias’ assessment for
each included study independently. If there was disagreement, the
authors met to reach consensus, consulting an independent third
review author if necessary.
Measures of treatment effect
We compared the post-treatment pain intensity scores between
the trial arms. Where possible, we calculated the proportion of
participants with a specific degree of pain relief and converted it
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into dichotomous information to yield the number of participants
who obtained a moderately important benefit (30% pain relief )
or a substantially important benefit (50% or more pain relief ) as
defined by the IMMPACT recommendations (Dworkin 2008).
We planned to calculate the risk ratio (RR) as the measure of
treatment effect and used this to calculate the number needed to
treat for an additional beneficial outcome (NNTB) for 30% and
50% pain relief. We also collected data on the duration of pain
relief postintervention where available.
For this update, we used the OMERACT 12 group’s recommen-
dations for minimally important difference for pain outcomes re-
ported on a continuous scale (Busse 2015). They recommend 10
mm on a 0-100 mm visual analogue scale (VAS) as the threshold
for minimal importance for average between-group change. They
highlight that should be interpreted with caution as estimates that
fall closely below this point may still reflect a treatment that bene-
fits a considerable number of patients. We used this threshold but
interpreted it cautiously.
Unit of analysis issues
No unit of analysis issues arose since we were unable to conduct a
meta-analysis due to insufficient data.
Dealing with missing data
Where insufficient data were presented to enter a study into the
meta-analysis, we contacted study authors to request access to the
missing data.
Assessment of heterogeneity
We planned to assess heterogeneity and its impact using the Chi
2 test and the I2 test (Higgins 2003; Higgins 2011). Where sig-
nificant heterogeneity (P < 0.1) was present, we planned to con-
duct subgroup analyses. Preplanned comparisons included CRPS-
I versus CRPS-II, children versus adults, and continuous versus
single block. However, no meta-analysis was possible.
Assessment of reporting biases
We considered the possible influence of publication/small study
biases on review findings. For studies that utilised dichotomised
outcomes, where possible, we planned to test for the possible influ-
ence of publication bias on each outcome by estimating the num-
ber of participants in studies with zero effect required to change
the NNTB to an unacceptably high level (defined as an NNTB of
10) as outlined by Moore 2008.
Data synthesis
We pooled results where adequate data supported this, us-
ing Review Manager 5 software (RevMan 2012). Separate pre-
planned meta-analyses included sympathetic blockade versus
sham/placebo procedure and sympathetic blockade versus no
treatment or usual care. We used a random-effects model to com-
bine the studies. We considered separate meta-analyses for short-
term (up to two weeks postintervention), mid-term (more than
two to less than seven weeks postintervention) and long-term
(seven weeks or longer postintervention) outcomes where we iden-
tified adequate data.
Assessment of quality of available evidence
For this update we used the GRADE approach to assess the quality
of evidence (Guyatt 2011a; Guyatt 2011b). Two reviewers inde-
pendently applied the GRADE criteria to each key comparison.
If there was disagreement, the authors met to reach consensus,
consulting an independent third review if necessary. We present a
summary of our judgements for each comparison in Appendix 5.
To ensure consistency of GRADE judgements, we applied the
following criteria to each domain equally for all key comparisons
of the primary outcome.
• Limitations of studies: downgrade once if more than 25%
of participants were from studies classified as being at a high risk
of bias across any domain, excluding the ’study size’ domain as
this is accounted for in the assessment of imprecision.
• Inconsistency: downgrade once if heterogeneity is
statistically significant and the I2 value is more than 40%. When
a meta-analysis was not performed we downgraded once if trials
did not show effects in the same direction.
• Indirectness: downgrade once if more than 50% of the
participants were outside the target group.
• Imprecision: downgrade once if fewer than 400 participants
for continuous data and fewer than 300 events for dichotomous
data.
• Publication bias: downgrade once where there is direct
evidence of publication bias or if estimates of effect based on
small scale, industry-sponsored studies raising a high index of
suspicion of publication bias.
Two review authors (NEO, BMW) judged whether these factors
were present. We considered single studies to be inconsistent and
imprecise, unless more than 400 participants were randomised
for continuous outcomes or more than 300 for dichotomous out-
comes. We applied the following definitions of the quality of the
evidence (Balshem 2011).
• High quality: We are very confident that the true effect lies
close to that of the estimate of the effect.
• Moderate quality: We are moderately confident in the effect
estimate; the true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different.
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• Low quality: Our confidence in the effect estimate is
limited; the true effect may be substantially different from the
estimate of the effect.
• Very low quality: We have very little confidence in the effect
estimate; the true effect is likely to be substantially different from
the estimate of effect.
’Summary of findings’ table
We included a ’Summary of findings’ table to present the main
findings in a transparent and simple tabular format. In particular,
we included key information concerning the quality of evidence,
the magnitude of effect of the interventions examined, and the
sum of available data on the outcome pain intensity, hand pain,
and duration of pain relief.
Subgroup analysis and investigation of heterogeneity
We assessed heterogeneity and its impact using the Chi2 test and
the I2 test (Higgins 2003; Higgins 2011). Where significant het-
erogeneity (P < 0.1) was present we planned to conduct subgroup
analyses. Preplanned comparisons included CRPS-I versus CRPS-
II, children versus adults, and repeated versus single blocks.
Where possible we used the proportion of people with adverse side
effects in each treatment group to calculate the number needed to
treat for an additional harmful outcome (NNTH).
Sensitivity analysis
When sufficient data were available, we conducted sensitivity anal-
yses on the effect of including/excluding studies classified as being
at unclear or high risk of bias.
R E S U L T S
Description of studies
Results of the search
The previous update of this review included twelve studies
(Aydemir 2006; Bonelli 1983; Carroll 2009; Meier 2009;
Nascimento 2010; Price 1998, Raja 1991; Rodriguez 2005;
Toshniwal 2012; Verdugo 1995, Wehnert 2002; Zeng 2003; com-
bined N = 386). For this update, we included an additional four
studies (Freitas 2013; Lim 2007; Rocha 2014; Yoo 2012; com-
bined N = 154]). As our modified criteria excluded studies with
follow-up of 48 hours or less, we excluded four studies from this
update that had been included in previous versions of this review
(Meier 2009; Raja 1991; Verdugo 1995; Wehnert 2002; combined
N = 79). Overall, we included 12 studies with 461 participants in
this update.
One new study is awaiting classification, as it was published as a
protocol for a trial and in abstract format only, and it is unclear
whether the trial was completed (Kostadinova 2012).
Figure 1 presents a flow chart of the search screening process for
the present update. We identified 461 studies through the database
search strategy and none from searching other sources. After re-
moving duplicates and screening titles and abstracts, we retrieved
the full text for five studies. Of these, we included four new studies
in the review.
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Figure 1. #Study flow diagram for updated searches
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For this update we attempted to contact the authors of two studies:
to retrieve essential data for Freitas 2013 and to check the status
of the trial and request a report if available for Kostadinova 2012.
Included studies
We present full details of the studies in the Characteristics of
included studies tables.
Study participants
All included studies evaluated only adult participants (Aydemir
2006; Bonelli 1983; Carroll 2009; Freitas 2013; Lim 2007;
Nascimento 2010; Price 1998; Rocha 2014; Rodriguez 2005;
Toshniwal 2012; Yoo 2012; Zeng 2003).
Nine studies included only people with upper limb CRPS treated
with stellate ganglion blockade (Aydemir 2006; Bonelli 1983; Lim
2007; Nascimento 2010; Rocha 2014; Rodriguez 2005; Toshniwal
2012; Yoo 2012; Zeng 2003), and two studies included only peo-
ple with lower limb CRPS treated with lumbar sympathetic block-
ade (Carroll 2009; Freitas 2013). The remaining study included a
mix of upper and lower limb CRPS (Price 1998).
Study designs
Two studies used a cross-over design (Carroll 2009; Price 1998),
and 10 employed a parallel design (Aydemir 2006; Bonelli
1983; Freitas 2013; Lim 2007; Nascimento 2010; Rocha 2014;
Rodriguez 2005; Toshniwal 2012; Yoo 2012; Zeng 2003). All in-
cluded studies were small, with total numbers of participants rang-
ing from 7 to 82.
LASB versus placebo
Two studies compared LASB versus placebo (Aydemir 2006; Price
1998).
Price 1998 (N = 7) compared stellate ganglion block (n = 4, 15
ml lidocaine 1%) versus lumbar sympathetic block (n = 3, 10 ml
bupivacaine 0.125%) with normal saline injection in people with
CRPS of the upper or lower extremities based on the IASP di-
agnostic criteria and investigated the proportion of participants
who experienced 50% pain relief. Price 1998 also measured the
duration of pain relief and the mean between-group difference
in pain relief on a visual analogue scale (VAS). Aydemir 2006
(N = 25) compared stellate ganglion lidocaine block (10 ml lido-
caine 1%) plus sham stellate ganglion ultrasound block (n = 9)
to a double-sham condition (sham stellate ganglion lidocaine (10
ml saline) and ultrasound blocks). Both groups received rehabil-
itation treatment. Investigators measured spontaneous pain post-
treatment and at one-month follow-up.
LASB versus other interventions
In contrast to the original version of this review, we included
studies, totaling nine, that compared LASB to other interven-
tions (Aydemir 2006; Bonelli 1983; Carroll 2009; Freitas 2013;
Lim 2007; Nascimento 2010; Rocha 2014; Toshniwal 2012; Yoo
2012).
Aydemir 2006 compared stellate ganglion lidocaine block (10 ml
of 1%) plus sham stellate ganglion ultrasound block (n = 9) to
stellate ganglion ultrasound ’block’ (consisting of ultrasound de-
livered non-invasively over the stellate ganglion) plus sham stellate
ganglion lidocaine block (10 ml of saline; n = 9). Both groups
received rehabilitation treatment. Investigators measured the pri-
mary outcome of spontaneous pain post-treatment and at one-
month follow-up.
Bonelli 1983 (N = 19) compared stellate ganglion block with
bupivacaine (15 ml of 0.5%; n = 10) versus intravenous regional
blockade (IVRB) with guanethidine (20 mg; n = 9) in patients
with reflex sympathetic dystrophy. The primary outcome was the
intensity of pain (measured using a 100 mm linear scale) measured
post-treatment at 15 minutes, 60 minutes, 24 hours and 48 hours
as well as at one and three months.
Carroll 2009 (N = 9, of whom seven completed the study) com-
pared sympathetic block with botulinum toxin A (75 units) plus
bupivacaine (10 ml of 0.5%) versus bupivacaine alone (10 ml of
0.5%) in people with CRPS of the lower extremity. The primary
outcome was the duration that pain (measured using a VAS) re-
mained below baseline levels.
Freitas 2013 (N = 40) compared sympathetic block of the lumbar
plexus with lidocaine and clonidine versus pulsed radiofrequency
treatment of the same structure. Investigators measured pain in-
tensity for up to six months follow-up.
Lim 2007 (N = 36) compared a course of five stellate ganglion
blocks with lidocaine versus a two-week course of corticosteroids
(prednisolone) in patients with CRPS following stroke. They used
a self developed four-point scale (0 to 3) of hand pain with passive
movement and followed patients up to 30 days from the start of
treatment.
Nascimento 2010 (N = 43) compared sympathetic block with li-
docaine (70 mg 1% lidocaine) versus sympathetic block with lido-
caine (70 mg 1% lidocaine) plus clonidine (30 µg) versus IVRB
with lidocaine plus clonidine (7.0 ml solution, 1% lidocaine, 1
µg/kg clonidine). Investigators measured intensity of pain (VAS)
and duration of pain relief post-treatment and at one-week follow-
up.
Rocha 2014 (N = 36) compared image-guided thoracic sympa-
thetic block with ropivacaine and triamcinolone versus injection
of the same agents into the subcutaneous space. Authors described
this comparison condition as an “active control” as it might be
predicted to induce physiological effects. This allowed blinding of
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participants. Investigators followed up participants using the Brief
Pain Inventory as an outcome measure at one month and one year.
This study did not report a responder analysis.
Toshniwal 2012 compared continuous stellate ganglion block
(SGB; n = 18; 280 ml, 0.125% bupivacaine at 2 ml/h for seven
days) versus continuous infraclavicular brachial plexus block (n
= 12; 400 ml, 0.125% bupivacaine at 5 ml/h for seven days) in
people with CRPS-I of the upper extremity. Both groups received
concurrent physiotherapy sessions. The primary outcome was the
subscale scores on the neuropathic pain scale measured over a four-
week period post-treatment.
Yoo 2012 (N = 42) compared stellate ganglion block with image
guidance to the same block versus no image guidance in partici-
pants with CRPS following stroke. Of note, the group with image
guidance received a higher dose of lidocaine (10 ml) than the non-
guided group (5 ml). Investigators measured pain intensity with a
VAS at two- and four-week follow-up.
LASB in addition to other therapies
Two studies evaluated the efficacy of LASB as an addition to
other therapeutic management (Rodriguez 2005; Zeng 2003).
Rodriguez 2005 evaluated physical therapy and pharmacologi-
cal treatment with or without SGB (N = 41 per group, 10 cc,
equal parts 2% lidocaine and 0.5% bupivacaine) in people with
upper limb CRPS with a confirmed sympathetic component to
their pain (50% pain reduction with screening, prerandomisation
SGB). Investigators measured pain intensity, therapeutic efficacy
(proportion with at least 50% pain reduction), and relapse rate
at two months post-treatment. Zeng 2003 compared SGB (dose
not reported) plus rehabilitation versus rehabilitation alone in a
group (N = 60) with shoulder-hand syndrome following stroke.
Pain (verbal rating scale) was measured at 10 and 20 days post-
treatment.
Excluded studies
In total, we excluded 26 studies. For this update, we excluded
one study at the full-text stage as it was not an RCT (Kastler
2013). In the last review we excluded two studies (Rodriguez 2006;
Rodriguez 2008), as it was not clear whether they represented
original trials in distinct cohorts or an expansion of the included
trial by Rodriguez 2005, comprising many of the same partici-
pants’ data. For this update we have reclassified these two studies to
Studies awaiting classification and have again attempted to contact
the study authors for clarification. See the table Characteristics of
excluded studies for details of all studies excluded from all versions
of this review.
We also identified one further study awaiting classification (
Kostadinova 2012).
Risk of bias in included studies
We present the summary results of the ’Risk of bias’ assessment in
Figure 2 and Figure 3. We considered no studies to be at low risk
of bias across all domains.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Only two studies clearly described an adequate randomisation pro-
cess (Freitas 2013; Toshniwal 2012); we considered the other ten
studies to be at unclear risk of bias for this domain. We judged
four studies as being at a low risk of bias for allocation conceal-
ment (Aydemir 2006; Rocha 2014; Rodriguez 2005; Toshniwal
2012), and we assessed six studies as being at unclear risk of bias
(Bonelli 1983; Freitas 2013; Lim 2007; Nascimento 2010; Yoo
2012; Zeng 2003). The remaining studies used a cross-over study
design (risk of bias for allocation concealment not applicable).
Blinding
We considered three studies to have blinded participants and per-
sonnel adequately (Aydemir 2006; Carroll 2009; Price 1998) (low
risk of performance bias). We considered six studies to be at un-
clear risk of bias across this domain (Bonelli 1983; Freitas 2013;
Nascimento 2010; Rocha 2014; Toshniwal 2012; Yoo 2012) as
though the interventions were distinguishable, both were active
invasive interventions. Three studies were at high risk of bias (Lim
2007; Rodriguez 2005; Zeng 2003;) as clinicians delivering the in-
terventions were not blinded or the intervention conditions were
clearly distinguishable. The outcome of interest for this review was
self-reported pain. In this situation, the patient acts as the assessor;
therefore risk of detection bias is primarily dependent on partici-
pant blinding. For blinding of outcome assessment, we judged five
studies to be at low risk of detection bias as they clearly reported
blinding of the participants (Aydemir 2006; Carroll 2009; Freitas
2013; Price 1998; Rocha 2014), four studies at unclear risk of bias
as it was unclear whether patients were adequately blinded (Bonelli
1983; Nascimento 2010; Toshniwal 2012; Yoo 2012), and three
studies were judged to have high risk of detection bias because
patients were not adequately blinded (Lim 2007; Rodriguez 2005;
Zeng 2003).
Incomplete outcome data
We considered seven studies to be at unclear risk of bias due to
incomplete outcome data (Aydemir 2006; Carroll 2009; Freitas
2013; Lim 2007; Rocha 2014; Rodriguez 2005; Yoo 2012) as a
result of the levels of drop-out reported or incomplete reporting
of attrition.
Selective reporting
We judged three studies to be at high risk of bias for this domain
due to incomplete reporting of pain scores (Freitas 2013; Price
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1998; Rodriguez 2005). Carroll 2009 carried an unclear risk of
bias for incomplete reporting of pain score at a secondary end
point.
Adequate sample size?
We judged all studies to be at high risk of bias with regard to
sample size as all had less than 50 participants per arm.
Adequate duration of follow-up?
We considered all but four studies to be at high or unclear risk
of bias based on inadequate duration of follow-up (Bonelli 1983;
Freitas 2013; Rocha 2014; Rodriguez 2005).
Other potential sources of bias
We judged two studies to be at high risk of bias for other reasons
(Bonelli 1983; Rocha 2014). In Bonelli 1983, the LASB group
had a significantly shorter duration of symptoms at baseline than
the IVRB guanethidine group, and participants were significantly
older. Rocha 2014 had average pain scores at baseline that differed
by greater than one point between groups , but authors did not
present tests for comparability at baseline. Three studies were at
unclear risk of bias (Freitas 2013; Yoo 2012). Freitas 2013 and
Rodriguez 2005 provided no baseline data, and neither Freitas
2013 nor Yoo 2012 gave details regarding concomitant treatments.
We judged the two cross-over studies to be at low risk of bias for
carry-over effects (Carroll 2009; Price 1998).
There were insufficient data to support a formal statistical analysis
of reporting/small study biases for any comparison.
Sources of funding and conflicts of interest
While not formally included within the ’Risk of bias’ assessment,
we extracted information regarding study funding and potential
conflicts of interest. Seven study reports offered no details re-
garding these issues (Aydemir 2006; Bonelli 1983; Freitas 2013;
Nascimento 2010; Price 1998; Yoo 2012; Zeng 2003).
Carroll 2009 declared that the authors had filed a patent for the
inclusion of botulinum toxin A in sympathetic blocks. Rodriguez
2005 declared financial support from governmental and non-
profit organisations. No study declared funding from industry
sources. Toshniwal 2012 and Rocha 2014 declared no conflict of
interest.
Effects of interventions
See: Summary of findings for the main comparison LASB for
pain intensity and duration of pain relief in adults with CRPS
For a summary of all core findings, see Summary of findings for
the main comparison.
LASB versus placebo
For the comparison of LASB versus placebo, we rated all evidence
as being of moderate quality.
Pain intensity
In Price 1998, there was no difference between lidocaine and nor-
mal saline; the same number of participants (6/7) achieved at least
50% pain relief at two weeks. In Aydemir 2006, spontaneous pain
scores were no different from baseline to post-treatment in either
the group receiving lidocaine plus sham ultrasound SGB (Z =
−0.18, P = 0.86) or in the group receiving sham lidocaine plus
sham ultrasound (Z = −0.76, P = 0.45). Authors did not report
between-group comparisons.
Duration of pain relief
Price 1998 evaluated the duration of pain relief, finding that when
local anaesthetic was administered, the mean duration of relief was
longer (three days versus 19.9 hours in the saline group). However,
short-term relief was similar in both groups. In Aydemir 2006,
spontaneous pain scores were no different from baseline to one-
month follow-up in either the group receiving lidocaine (plus sham
ultrasound SGB; Z = −1.05, P = 0.29) or in the group receiving
sham lidocaine and sham ultrasound (Z = −0.68, P = 0.50). Au-
thors reported no between-group comparisons. None of the in-
cluded studies reported postintervention analgesic requirements.
Adverse Events
Price 1998 and Aydemir 2006 did not report adverse events.
LASB versus other interventions
Pain relief
Most comparative studies reported no significant difference in pain
between groups (Bonelli 1983; Freitas 2013; Nascimento 2010;
low to very low quality evidence). Aydemir 2006 did not explic-
itly report between-group differences, although they did not find
any within-group differences in spontaneous pain scores between
baseline and post-treatment nor at one-month follow-up in either
the group receiving lidocaine SGB plus sham ultrasound SGB (Z-
scores listed above) or in the group receiving ultrasound SGB plus
sham lidocaine (Z = −0.59, P = 0.55; Z = −0.63, P = 0.53, re-
spectively; low quality evidence). Due to the variation in the in-
terventions, there were not adequate data to allow pooling of the
results.
Lim 2007 reported no significant difference in hand pain intensity
(scale from 0 to 3) between LASB plus corticosteroid versus oral
corticosteroids at 15-day follow-up (mean difference 0.00, 95%
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confidence interval (CI) −0.35 to 0.35; very low quality evidence)
and a statistically significant difference in favour of LASB with
steroid at 30 days (mean difference 0.40, 95% CI −0.69 to −0.11;
very low quality evidence).
Rocha 2014 reported that thoracic LASB with ropivacaine and
steroid did not result in a statistically significant difference in av-
erage pain scores compared to injection of the same agents into
the subcutaneous space (described as an “active placebo” at one
month (0 to 10 scale mean difference −1.25, 95% CI −3.20
to 0.70; very low quality evidence), but there was a statistically
significant difference at one-year follow-up in favour of thoracic
LASB (mean difference −2.39, 95% CI −4.72 to −0.06; very
low quality evidence). While not significant at one-month follow-
up, the point estimate at both time points exceeds our threshold
for clinical importance. However, it is worth noting that at one-
year follow-up, attrition in the active group was 16% and in the
control group 26%, introducing a possible risk of bias.
Toshniwal 2012 reported significantly lower short-term pain
scores (on a 0 to 10 scale) in favour of the group receiving the
continuous infraclavicular brachial plexus block versus the group
receiving the continuous stellate ganglion block. Specifically, at
30 minutes, 2 hours and 12 hours, those receiving the continu-
ous brachial plexus block had significantly lower intensity of pain
(0.7, 0.5, and 0.7, respectively) and unpleasantness of pain (0.7,
0.7, and 0.8, respectively) compared with those receiving a con-
tinuous stellate ganglion block (intensity: 3.3, 2.7, and 1.9; un-
pleasantness: 3.0, 2.7, and 1.9). Dull pain intensity scores were
significantly reduced for the brachial plexus block group versus the
stellate ganglion block group at 2 hours (0.1 versus 2.4), 12 hours
(0.6 versus 1.9), and 24 hours (1.3 versus 2.6) with deep pain also
significantly reduced at these time points (2 hours −0.1 versus
2.3; 12 hours −0.7 versus 1.6; 24 hours −1.4 versus 2.4), as well
as at 30 minutes postcannulation (0.1 versus 2.3). There were no
statistically significant differences between groups for short-term
scores on any of the other Neuropathic Pain Scale components.
Furthermore, there was no evidence of increased effectiveness for
long-term pain relief in one group over the other and no between-
group differences at any other time points. There was no statisti-
cal comparison of quality of pain differences between groups. We
rated this evidence as being of low quality.
Yoo 2012 found no statistically significant or clinically important
difference between image-guided and non-guided stellate ganglion
block at two weeks postinjection (0 to 10 pain VAS mean differ-
ence −0.58, 95% CI −1.51 to 0.35; very low quality evidence);
there was a statistically significant but clinically unimportant dif-
ference at four weeks postinjection (mean difference −0.74, 95%
CI −1.36 to −0.12; very low quality evidence) in participants
with CRPS following stroke.
Duration of pain relief
Carroll 2009 reported a significantly longer duration of analgesia
in the botulinum toxin A group (median time to analgesic failure
71 days (95% CI 12 to 253; low quality evidence) compared with
bupivacaine alone (< 10 days, 95% CI 0 to 12; P < 0.02; low quality
evidence). However, while the authors reported that pain intensity
declined significantly in the botulinum toxin A group, they did
not provide numeric pain scores for either treatment group.
Adverse events
Only six studies provided specific data regarding adverse events,
and the level of detail of this reporting was mixed.
Carroll 2009 reported moderate adverse events in one participant
(14.2%) following the botulinum toxin type A LASB. This par-
ticipant had significant nausea and emesis that began five5 hours
after the injection and lasted two days, resolving spontaneously.
Freitas 2013 reported that paraesthesia during needle positioning
in “1 out of 10” in the LASB group and “2 out of 10” in the pulsed
radiofrequency group. This is likely to be an error as it suggests
that there were 20 participants in total while the trial reports 40
participants. The study reports that all participants in both groups
reported soreness at the injection site lasting five to seven days.
Nascimento 2010 also found mild adverse events for all three
groups. The SGB group receiving lidocaine and clonidine (gGroup
2) reported the highest frequency of adverse events: 93.3% re-
ported drowsiness (14/15), 13.3% dizziness (2/15), 13.3% hoarse-
ness (2/15), 6.7% reported pain at the injection site (1/15), and
26.7% reported a feeling of dry mouth (4/15). The SGB group
receiving only lidocaine (gGroup 1) reported the lowest frequency
of adverse events, with nausea occurring in 6.5% (1/14), dizziness
in 14.3% (2/14), hoarseness in 6.5% (1/14), and pain at the injec-
tion site in 6.5% (1/14). Lastly, the group receiving the IVintra-
venous (IV) regional block with lidocaine and clonidine (gGroup
3) reported drowsiness (46.1%; 6/13) and dizziness (7.7%; 1/13).
Rocha 2014 reported a similar overall rate of minor adverse events
following thoracic blockade or subcutaneous injection with lo-
cal anaesthetic and steroid and no major adverse events. Minor
eventsThese included dizziness, blurred vision, puncture pain, in-
creased pain, headache, nausea, vomiting, dysphagia, hoarseness,
haematoma, dyspnoea, shivering, cold feeling, face swelling, and
mouth numbness. Of note, 65% of participants in both groups
reported “puncture pain”;, 24% in the thoracic block group re-
ported dyspnoea compared with 6% in the subcutaneous group.
35%Thirty-five per cent in the thoracic block group reported
dizziness compared to 12% in the subcutaneous group. Twenty-
four per cent in the thoracic block group reported dizziness com-
pared to no participants in the subcutaneous group.
Toshniwal 2012 found adverse events in both groups. In the con-
tinuous stellate ganglion block group, Horner’s syndrome was
most common (94.7%) while initial motor weakness was the most
common adverse event in the continuous infraclavicular brachial
plexus group (100%). Positive catheter tip culture occurred in
61.1% (11/18) of the stellate ganglion block group and in 8.3%
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(1/12) in the brachial plexus group; investigators observed no signs
of infection at the catheter site were observed in either group.
Catheter migration was found in 5.2% (1/19) of the stellate gan-
glion block group (versus 7.1% (1/14) of the brachial plexus
group). Lastly, hoarseness of voice (for initial 12 hours) was found
in 16.7% (3/18) of participants in the stellate ganglion block group
reported hoarseness of voice (for initial 12 hours).
Yoo 2012 reported no adverse events in the group who received
ultrasound guided blocks and two haematomas at the injection
site for those who received unguided blocks.
LASB in addition to other interventions
Pain relief
Zeng 2003 and Rodriguez 2005 investigated the effectiveness of
adding LASB to rehabilitation versus rehabilitation or medication
alone. Zeng 2003 found no benefit of adding LASB at 10 days
(0-10 Verbal Rating scale mean difference 0.2, 95% CI −1.3 to
1.7; very low quality evidence) or 20 days (mean difference 0.1,
95% CI −0.97 to 1.17; very low quality evidence). Rodriguez
2005 reported treatment efficacy (proportion with at least 50%
pain reduction) at the two-month follow-up to be 46% in favour
of the SGB group, an absolute risk reduction of 17% in favour of
the SGB group with a number needed to treat for an additional
beneficial outcome (NNTB) of 6. The NNTB suggests that six
people with CRPS would need to be treated with SGB (in addition
to physical and pharmacological therapy) to prevent one relapse.
There was a higher relapse rate in the control group (37%) versus
the SGB group (20%) (hazard ratio (HR) 2.7, 95% CI 1.1 to
6.7; very low quality evidence). The Kaplan-Meier estimates of the
cumulative probability of not having a relapse at two months was
80% in the SGB group and 63% in the control group. However,
this study did not report data for pain intensity or the proportion
who achieved meaningful pain relief.
Duration of pain relief
No studies specifically presented data on the duration of pain relief
for this comparison.
Adverse events
Zeng 2003 and Rodriguez 2005 did not report adverse events.
D I S C U S S I O N
Summary of main results
The objective of this review was to assess the efficacy of LASB for
the treatment of pain in CRPS and to evaluate the incidence of
adverse effects of the procedure.
Previous versions of this review revealed the scarcity of published
evidence to support the use of LASB for CRPS and raised questions
about its efficacy.
LASB versus placebo or no treatment
This update reveals little progress in developing high quality evi-
dence to support the use of LASB for CRPS since the last update in
2013. There are only two placebo-controlled randomised studies
that met our modified inclusion criteria for this update (Aydemir
2006; Price 1998), both of which have very small sample sizes.
We can draw no firm conclusions from this evidence. It is notable
that the results to date are not suggestive of a significant effect of
LASB over placebo even in the very short term (30 minutes to two
hours), the time frame that theory would suggest local anaesthetic
is likely to have its maximum benefit. We could not estimate the
duration of pain relief, if any.
LASB versus other interventions
In a change from the original version of this review, we took the
decision to include trials that compared LASB with alternative in-
terventions or that evaluated the effect of adding LASB to other
treatments. We identified a number of such studies investigating
a range of comparisons, and the majority of these demonstrated
no significant difference between the intervention and control
groups. It is notable that in one small study (Bonelli 1983), LASB
did not demonstrate superior effectiveness when compared to in-
travenous regional blockade (IVRB) with guanethidine, an inter-
vention for which there is consistent evidence of no effect (Jadad
1995; McQuay 1997; O’Connell 2013).
One small study (N = 36) at high risk of bias suggests a potentially
clinically important effect for thoracic sympathetic blockade with
bupivacaine and triamcinolone on average daily pain at one month
and one year when compared to injection of the same agents into
the subcutaneous space, though this difference was not statistically
significant at one- month follow-up (Rocha 2014). The subcuta-
neous injection in this study was used as an active control condi-
tion, and might be expected to have systemic effects.
Carroll 2009 provided limited evidence that, compared with LASB
alone, sympathetic blockade with botulinum toxin A added to
local anaesthetic may prolong analgesia. Another single study,
Rodriguez 2005, provided limited evidence to suggest that when
added to usual physical therapy and pharmacological treatment,
LASB may reduce the risk of relapse, but we found this study to
be at high risk of bias across multiple domains; it did not report
data for pain relief, and the lack of a sham condition raises the
possibility that the observed improvement may have resulted from
non-specific effects. In contrast, Zeng 2003 found no benefit of
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adding cervical sympathetic blockade to usual comprehensive re-
habilitative treatment for pain outcomes.
There is limited evidence that, compared with continuous in-
fraclavicular brachial plexus blocks, continuous stellate ganglion
LASB results in less relief in short-term pain intensity, pain un-
pleasantness, deep pain and dull pain (Toshniwal 2012). The same
study also provides limited evidence of no difference in longer-
term pain relief (up to four weeks) between groups (Toshniwal
2012).
Given the limited evidence available and the various sources of
potential bias and uncertainty, we conclude that there is little cred-
ible evidence to support the use of LASB for CRPS and that the
majority of the limited evidence available suggests that LASB may
be ineffective.
Adverse events
The reporting of adverse events in the identified studies was in-
consistent and limited. Given this lack of reporting and the small
size of all of the included studies, we cannot confidently draw
conclusions regarding the safety of LASB. While those adverse
events that have been reported appear to be minor, it is not cur-
rently possible to rule out the potential for rare but serious adverse
events. To obtain a better estimate of the incidence and nature of
adverse events, it might be necessary to review evidence from non-
randomised observational study designs, but that was beyond the
scope of this review.
Overall completeness and applicability of
evidence
By undertaking a systematic search of unpublished and grey lit-
erature and consulting experts in the field, we have limited the
risk of excluding important and relevant evidence. We judged all
of the included studies as being at unclear risk of bias in at least
one domain, reflecting a common lack of clarity in many study
reports. We deemed three as being at high risk of bias specifically
for the selective reporting of outcomes. This represents a signifi-
cant challenge to a confident interpretation of an already limited
evidence base.
We attempted to contact the authors of seven studies, with mixed
success. Two responded and provided available data (Nascimento
2010; Toshniwal 2012). However, as we were unable to source two
studies (Kostadinova 2012; Salinas Cerda 1997), did not receive
a response from one to provide full data (Freitas 2013), and were
unable to include two studies due to lack of clarity over whether the
participant population overlapped with another included study (
Rodriguez 2006; Rodriguez 2008), it is possible that we are missing
relevant data.
Quality of the evidence
We did not judge any of the included studies to be at low risk of bias
across all domains. Indeed, all but two studies carried an unclear
risk of bias for random sequence generation and all but four for
allocation concealment. These factors have been demonstrated to
exaggerate the effects of studies, particularly those with subjective
outcomes, such as pain (Schulz 1995; Wood 2008). We assessed
all studies to be at high risk of bias for inadequate sample size and
only four studies to be at low risk of bias for adequate duration
of follow-up. Small studies may well be underpowered to detect
a clinical effect, but conversely there is empirical evidence that
small published clinical trials in pain have a tendency to exaggerate
treatment effects (Moore 2010; Nüesch 2010). These numerous
sources of potential bias might alone explain any observed positive
effects in the included studies. Thus, all of the evidence identified
should be interpreted with caution.
Applying the GRADE approach, ratings across all comparisons
were either low or very low quality except for the comparison of
LASB versus placebo, which was of moderate quality. This rating
is the result of the criteria we decided upon a priori when updat-
ing the searches. However, this moderate rating still merits some
caution, since it is based on so few data. It is our view that for
future updates, the rating of imprecision might be downgraded
twice in the event that a comparison consists of fewer than 100
participants. Since each comparison consists of only one or two
very small studies, and since all studies are at unclear or high risk of
bias across various domains, it would be reasonable to characterise
the entire body of included evidence as of low or very low quality.
Potential biases in the review process
While we have attempted to identify all eligible trials using a com-
prehensive search strategy, we may have still missed some key lit-
erature. Only three included studies used a positive response to
a prior LASB to attempt to establish sympathetically maintained
pain as part of their inclusion criteria (Carroll 2009; Price 1998;
Rodriguez 2005). This speaks to a wider issue concerning the use
of LASB in CRPS. It is possible that LASB might only be effective
in a subgroup of people with CRPS with sympathetic dysfunction,
or perhaps in people with other characteristics. However, to date
evidence of predictors of a positive response to LASB are elusive
(Sethna 2012).
The decision to exclude studies with only very short term follow-
up (≤ 48 hours) has led to the exclusion of studies that had been
included in previous updates of this review. We took this decision
on the basis that such studies are of more value in terms of inves-
tigating the diagnostic potential of LASB, which was not the pur-
pose of our review. These studies do not provide clinically useful
information in terms of treatment effectiveness over a reasonable
period of time. This review focused on pain as a primary outcome
and did not consider outcomes such as function or other clinical
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signs. However, LASB is commonly conducted with the primary
goal of pain relief.
Agreements and disagreements with other
studies or reviews
Our results do not change the overall conclusions of earlier ver-
sions of this review. Similarly a number of earlier systematic re-
views have included evaluations of the evidence for LASB, and all
have similarly agreed that the evidence is limited and that there
is no clear evidence for the efficacy of LASB (Forouzanfar 2002;
Perez 2010; Tran 2010). Van Eijs 2011 recommended that LASB
be considered for the treatment of CRPS if conservative multi-
disciplinary management has failed. However, they rated the ev-
idence for the effectiveness of CRPS as level 2B+, characterised
as “multiple RCTs, with methodologic weaknesses, yield contra-
dictory results better or worse than the control treatment. Bene-
fits closely balanced with risk and burdens, or uncertainty in the
estimates of benefits, risk and burdens.” This classification of the
evidence seems consistent with our own conclusions, though we
feel this level of evidence precludes clinical recommendations.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
For people with CRPS
LASB is a treatment that may be offered for CRPS to help re-
duce pain and other symptoms. There is a scarcity of published
evidence and a lack of high quality evidence to support or refute
its effectiveness, though the available evidence is not encouraging.
Due to the scarcity of evidence it is not possible to draw confident
conclusions about the safety of LASB. People should consider this
information when deciding whether to agree to receive the treat-
ment.
For clinicians
There is a scarcity of published evidence and a lack of high quality
evidence to support or refute its effectiveness, though the available
evidence is not encouraging. One study, judged to be at high risk
of bias, provides very low quality evidence that LASB may reduce
the risk of recurrence of pain when added to rehabilitation and
standard pharmacological care, and one study, also judged to be
at high risk of bias, suggests that thoracic sympathetic block with
local anaesthetic and corticosteroid may be effective. However, on
the basis of such evidence it is not possible to make any clinical
recommendations. Due to the scarcity of evidence it is not possible
to draw confident conclusions about the safety of LASB.There is
currently little credible evidence to support the use of LASB for
CRPS.
For policy makers and funders
The available evidence relating to the effectiveness of LASB
for CRPS is not compelling. While there is substantial uncer-
tainty regarding the effectiveness of alternative therapeutic options




If LASB is to continue to be offered to people with CRPS, there
is a clear need for further, better quality research into its efficacy.
It seems likely that the best chance of delivering high quality tri-
als is through multicentre, collaborative research projects that can
recruit from larger clinical populations. While many studies in-
vestigate the effect of adding therapeutic agents to LASB, there
remains substantial uncertainty regarding the efficacy of simple
local anaesthetic blockade for CRPS.
Design
Reducing this uncertainty requires adequately powered trials that
utilise placebo controls, ensure adequate blinding and confirm
the technical adequacy of the block. Future trials should use es-
tablished diagnostic criteria and clearly report the type of CRPS
under investigation. Trials should also consider the IMMPACT
recommendations for the design of trials in pain to ensure that
outcomes, thresholds for clinical importance and study designs are
optimal (Dworkin 2008; Dworkin 2009; Dworkin 2010; Turk
2008a; Turk 2008b).
Measurement (endpoints)
Future trials should measure both immediate pain relief and long-
term (≥ 6 month) outcomes from LASB. Furthermore, future
trials should adhere to the CONSORT guidance on standards
of reporting and should clearly report all adverse events (Altman
2012).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aydemir 2006
Methods RCT, parallel design
Participants N = 25; divided into 3 groups (group 1: n = 9; group 2: n = 9; group 3: n = 7)
Mean age (SD):
Group 1: 21.9 years (1.05)
Group 2: 21.4 years (0.73)
Group 3: 21.1 years (0.38)
Sex: not reported.
Upper limb CRPS-I (dominant arm: group 1, n = 6; group 2, n = 9; group 3, n = 2);
excluded if had SGB block in last month
Diagnostic criteria: IASP (Bruehl 1999)
Duration of symptoms:
Group 1 (0-3 months, n = 5; 3-6 months, n = 2; > 6 months, n = 2)
Group 2 (0-3 months, n = 6; 3-6 months, n = 2; > 6 months, n = 1)
Group 3 (0-3 months, n = 5; 3-6 months, n = 0; > 6 months, n = 2)
Type of initiating injury:
Group 1 (trauma, n = 7; fracture, n = 2; idiopathic, n = 0)
Group 2 (trauma, n = 2; fracture, n = 5; idiopathic, n = 2)
Group 3 (trauma, n = 3; fracture, n = 4; idiopathic, n = 0)
Concomitant treatments: all groups received 21 sessions of physiotherapy, which in-
volved exercises, contrast baths, transcutaneous electrical nerve stimulation (TENS), and
pneumatic compression. If necessary, all groups had access to medical treatment, which
involved 500 mg oral paracetamol pill, maximum of six tablets (3 g) per day
Medicolegal factors: not reported
Previous treatment: not reported
Interventions Group 1: stellate ganglion lidocaine block (real) plus sham stellate ganglion ultrasound
block
Group 2: stellate ganglion ultrasound block (real) plus sham stellate ganglion lidocaine
block
Group 3: sham stellate ganglion lidocaine block and sham stellate ganglion ultrasound
block
For the purpose of this review, we included comparisons between group 1 and group
3 as placebo-controlled and comparisons of group 1 and group 2 as comparison with
another active intervention
SGB lidocaine (real):
Location: C6 level; 1.5 cm lateral to central line, 4-5 cm deep
Dosage: 10 ml of 1% lidocaine
Number of blocks performed: 10
Eval. of technical adequacy of block: No.
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Aydemir 2006 (Continued)
SGB (sham):
Identical site, but injected 10 ml of saline.
Number of blocks not reported.
SGB ultrasound (real):
Probe size of 1 cm2; 5 min of intermittent ultrasound at 3 watt/cm2 over the affected
site (over stellate ganglion)
Number of treatments not reported
SGB ultrasound (sham):
5 min, no energy delivered
Number of treatments not reported
Outcomes Spontaneous pain:
0-10cm visual analogue scale
Outcomes measured pretreatment, post-treatment, and at one-month follow-up
Adverse events/side effects not reported
Country of origin Turkey
Study aim To investigate the efficacies of stellate ganglion blockage (SGB) with lidocaine and ul-
trasound in CRPS
Notes This study was translated and interpreted by a researcher fluent in Turkish. The study
author, TS, worked with the researcher to fully interpret and score
Conflict of interests not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomized”
Comment: Method of randomisation not reported
Allocation concealment (selection bias) Low risk Envelope method used to conceal allocation; group assignment
generated by an independent person
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind”
Comment: reported that participants and personnel blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Reported that outcome assessors blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Drop-outs/withdrawals not reported
Selective reporting (reporting bias) Low risk All prespecified outcomes were adequately reported on
Adequate sample size? High risk Group 1, n = 9; group 2, n = 9; group 3, n = 7
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Aydemir 2006 (Continued)
Adequate duration of follow-up? Unclear risk One-month follow-up
Free of other bias? Low risk Pain scores were not significantly different between groups at
baseline; identical timing of outcome assessment between groups
Bonelli 1983
Methods RCT, parallel design
Participants N = 19
Mean age (SD): 52.33 years (5.04)
Sex: not reported
Diagnosis of RSD following peripheral nerve injury
At least 3 of the following clinical signs: hyperpathia, allodynia, vasomotor disturbance,
trophic signs, oedema, limited motion
Mean (SD) duration of pain:
Stellate ganglion block group: 6.55 (3.94) months
IVRB guanethidine group: 17.55(14.9) months
Previous treatment not reported; concomitant treatment not reported
2 lost to follow-up at 3 months in SGB group
Baseline pain (0-100 scale) mean (SD):
Stellate ganglion block group: 70.5 (27.36)
IVRB guanethidine group: 65 (25.46)
Medico-legal factors: not reported
Interventions SGB (n = 10) versus IVRB guanethidine block (n = 9); treatment period of 16 days
SGB: bupivacaine (0.5%) 15 ml
No. of blocks: 8 (1 every other day for 16 days)
Evaluation of adequacy of block? Skin temperature, plethysmographic wave
IVRB guanethidine (20 ml), heparin (500 µl), isotonic saline (25 ml)
No. of blocks: 4 (every 4 days)
Outcomes Pain: 100 mm linear scale (specific details not reported)
Pain measured at baseline and post-treatment at 15 min, 60 min, 24 h, 48 h, 1 month
and 3 months
Adverse events only mentioned in discussion (alludes to none in either group)
Country of origin Italy
Study aim To compare the effects of regional IVRB with guanethidine with stellate ganglion blocks
in people with severe RSD following peripheral nerve injury of the upper limb
Notes Conflicts of interest not stated
Risk of bias
Bias Authors’ judgement Support for judgement
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Bonelli 1983 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomly allocated to two groups”
Comment: Method of randomisation not reported
Allocation concealment (selection bias) Unclear risk Allocation concealment not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participant blinding not reported. The interventions are likely
to be distinguishable. Unsure if participants aware of study hy-
pothesis
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data post-treatment and one-month follow-up. 3
months: 2/10 missing from SGB group, no missing data for
IVRB group
Selective reporting (reporting bias) Low risk All outcomes listed in methods were reported in the results
Adequate sample size? High risk N = 19; n = 10 stellate ganglion block group, n = 9 regional IV
guanethidine
Adequate duration of follow-up? Low risk Follow-up of 3 months
Free of other bias? High risk At baseline, SGB group had a significantly shorter duration of
symptoms than the IVRB guanethidine group (mean (SD): 6.
55 (3.94) months versus 17.55 (14.9) months; P < 0.05) and
were significantly older (mean (SD): 52.33 (5.04) years versus
42.77 (4.65) years; P < 0.01)
Carroll 2009
Methods RCT cross-over
Participants N = 9
Age mean (range) 49.4 (38-67)
Sex: 1 male
Lower limb CRPS-I, with duration of pain of at least 6 months, spontaneous pain rating
> 6/10, unsuccessful therapy with at least 2 non-opioid medications (for neuropathic
pain), at least a 50% reduction in pain for > 5 h but < 2 weeks from a previous lumbar
sympathetic injection
Inciting events: tarsal tunnel surgery n = 1, bunionectomy/cast n = 1, crush injury n =
1, plantar fasciectomy n = 1, foreign body removal n = 1, ankle arthroscopy n = 1, ankle
fracture/cast n = 1, metatarsal fracture n = 1, back surgery n = 1
Diagnostic criteria: IASP (Merskey 1994)
Medico-legal factors: not reported
Mean duration of pain (range): 3.8 years (2-14)
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Carroll 2009 (Continued)
Baseline mean pain levels, 10 cm VAS (range): 7.2 cm (4.7-8.9)
Concomitant treatments: not reported but participants asked not to cease existing ther-
apies, but not to start new therapies during study period
Interventions Lumbar sympathetic blocks:
Anterolateral border of L2 vertebral body, fluoroscopy guided
Active: 10 ml of 0.5% bupivacaine with an added 75 units botulinum toxin A
Control: 10 ml of 0.5% bupivacaine
Outcomes Primary outcome: time to analgesic failure (time for pain to return to baseline level)
Daily pain intensity - 10 cm VAS, measured for 7 days prior to first injection and recorded
daily until participants reported their pain returned to baseline or 1 month (whichever
was longer)
Adverse events reported
Country of origin USA
Study aim To determine whether adding BTA to lumbar sympathetic blockade increases the dura-
tion of analgesia
Notes Authors declared that they had filed a patent for BTA in sympathetic blocks
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly assigned to which injection they
received first”
Comment: method of randomisation not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “All physicians and patients involved in the study
were blinded to which injection contained botulinum toxin A.
Data were not unblinded for any patient until the study was
completed, and no interim analyses were performed”; “in the
crossover injection, the patient received an identical injection”
Comment: injections were identical and participants blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: as above
Comment: self reported outcomes and participants were blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 2/9 participants did not complete the study (one due to tech-
nical issues related to the block - malpositioning of the needle
- and one because outcome forms were not returned). Only 1
participant received BTA first, and this participant dropped out
Due to complete blinding and use of a cross-over study design,
the effect that this drop-out has on the results is unclear
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Carroll 2009 (Continued)
Selective reporting (reporting bias) Unclear risk Full data not presented for the secondary end point (VAS pain
scores over time); comparison of within-injection group change
over time provided, but comparison of between-injection group
differences not provided
Adequate sample size? High risk N = 9
Adequate duration of follow-up? Unclear risk Quote: “Patients continued to record daily VAS until they re-
ported their pain had returned to baseline or 1 month, whichever
was longer”
Comment: Follow-up was observed until pain returned to base-
line levels - for some this was only 4 weeks
Free of other bias? Low risk Cross-over study design ensured similarity between groups; par-
ticipants allowed to continue current medications but could not
start new medications
Quote: “patients were eligible for their crossover injection 1
month after they reported their pain had returned to baseline”
Comment: 1 month washout period observed, after pain had
returned to baseline levels
Freitas 2013
Methods RCT parallel
Participants N = 40 (though adverse event reporting implies 20 and no CONSORT flowchart pre-




Diagnostic criteria: IASP Bruehl 1999
Duration of pain prior to block: > 6 months
Type of initiating injury: not reported
Concomitant treatments: not reported
Medico-legal factors: excluded if pending litigation
Previous treatment: unresponsive to medication and physiotherapy (such as oral
gabapentin 2400 mg/d, oral amitriptyline 100 mg/d, and oral carbamazepine 1000 mg/
d and physiotherapy for more than 6 months
Interventions Group 1: LASB lumbar plexus sympathetic block L2-3 and L3-4. 15 ml lidocaine and
100 mcg clonidine at each level
Group 2. Pulsed radiofrequency (PRF) lumbar plexus L2-3 and L3-4, x3 120sec cycles
at each level at 42º C. 1 ml of 2% lidocaine injected at each level
Evaluation of technical adequacy of blocks: no
Number of blocks: 1 per site, on 1 occasion
Concomitant treatments: not reported
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Freitas 2013 (Continued)
Outcomes Pain intensity VAS, neuropathic pain scale. No numerical data provided
SF-36. Means reported but no measures of variance
Statistically significant difference seen in “hot pain” at “final score” but this time point
is not clearly defined - likely 6 months
Adverse events: “2 out of 10” had paraesthesia following PRF. “1 out of 10” had paraes-
thesia following LASB. Note; this implies 20 rather than 40 participants
Country of origin Brazil
Study aim To determine whether percutaneous PRF applied directly to the sympathetic lumbar
plexus was more effective than lumbar sympathetic blocks, and, if so, whether this could
be achieved without the risks associated with traditional ablative procedures
Notes Conflicts of interest not stated.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomized to either PRF or sympathetic
lumbar block according to computer generated random num-
bers”
Allocation concealment (selection bias) Unclear risk Comment: no information given
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Personnel not blinded however, comparison is be-
tween two active invasive interventions
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: Participants blinded to group assignment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 1 participant in pulsed radiofrequency group dropped out - rea-
sons unclear and unclear whether data missing or excluded
Selective reporting (reporting bias) High risk Pain outcome data are not reported in numerical format
Adequate sample size? High risk N = 40 entered the study but reporting of adverse events suggests
20 participants
Adequate duration of follow-up? Low risk 6-month follow-up
Free of other bias? Unclear risk No baseline data presented; no detail given regarding concomi-
tant treatments
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Lim 2007
Methods Parallel RCT
Participants N = 38
Mean age (SD):
Group 1: 61.4 years (10.1)
Group 2. 58.7 years (12.1)
Sex: 21 female, 17 male
Upper Limb CRPS poststroke
Diagnostic criteria: unclear though described a “three phase bone scan test”
Duration of symptoms: not reported
Type of initiating injury: stroke.
Concomitant treatment: conservative physical therapy including passive joint move-
ments
Medico-legal factors: not reported
Previous treatment: not reported
Interventions Group 1: LASB stellate ganglion, lidocaine
Dosage: 10 ml 0.5% lidocaine
Number of blocks: 5 blocks: 1 every 3 days for 15 days
Evaluation of technical adequacy of block: not reported
Group 2: oral corticosteroids for 14 days. 60 mg of oral prednisolone was administered
in two 30mg doses depending on the hormone cortisol rhythm on days 1-3, and applied
40 mg on days 4-6, 30 mg on days 7-9, and 20 mg on days 10-12. Single dose of 10 mg
was administered on days 13-14. Oral administration was stopped after 14 days
Outcomes 0-3 scale hand pain with passive movement or palpation. Measured at 15 and 30 days
from start of treatment
Country of origin Korea
Study aim To compare the therapeutic effects between stellate ganglion block and steroid therapy
in poststroke complex regional pain syndrome
Notes Adverse events not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: no details reported
Allocation concealment (selection bias) Unclear risk Comment: no details reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: Personnel not blinded. Non-invasive control quali-
tatively different to active intervention
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Lim 2007 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: Inadequate blinding of participants
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: no information reported on attrition
Selective reporting (reporting bias) Low risk Comment: outcomes adequately reported
Adequate sample size? High risk Comment: N = 38
Adequate duration of follow-up? Unclear risk Comment: 30 days follow-up
Free of other bias? Low risk Comment: no other bias detected
Nascimento 2010
Methods RCT, parallel
Participants N = 43
Mean age (range):
Group 1: 37.7 years (27-54)
Group 2: 38.6 years (25-50)
Group 3: 39.0 years (27-50)
Sex:
Group 1 (n = 14): 1 male
Group 2 (n = 15): 1 male
Group 3 (n = 14): 1 male
Upper extremity CRPS-I
Diagnostic criteria: IASP (Merskey 1994)
Mean duration of pain (range):
Group 1: 24.2 months (3-72)
Group 2: 24.2 months (8-72)
Group 3: 22.3 months (2-48)
Mean baseline pain intensity (SE), 10 cm VAS scale:
Group 1: 8.7 cm (0.3)
Group 2: 8.7 cm (0.3)
Group 3: 8.3 cm (0.3)
Inciting event:
Repetitive strain injury n = 18, carpal tunnel syndrome n = 11, late postsurgical pain n
= 8, fracture and long-lasting immobilisation n = 3, stab wound n = 2, unknown n = 1
Previous treatment for CRPS: unsuccessful use of tricyclic antidepressants, gabapentin,
opioids or anti-convulsants
At admission all free of drugs.
Medico-legal factors: not reported
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Nascimento 2010 (Continued)
Interventions Group 1: SGB, anterior paratracheal approach, fluoroscopy-guided, 70 mg 1% lidocaine
Group 2: SGB, identical approach,70 mg 1% lidocaine + 30 µg clonidine
Group 3: IVRB 7.0 ml solution 1% lidocaine with 1 µg/kg clonidine. Tourniquet
pressure released 30 min later
Evaluation of adequacy of block? yes, temperature checked
No. of blocks: 5, x 1 weekly
Outcomes Pain intensity 0-10 cm VAS (anchors “no pain” to “worst pain imaginable”)
Pain was measured immediately before and soon after the end of each procedure. Pain
intensity scored daily. Pain measured one week after the last procedure
Duration of analgesia calculated as the interval between the end of the procedure and
the time at which VAS ≥ 3 was recorded
Adverse events reported
Country of origin Brazil
Study aim To compare the efficacy of IVRB produced by combining lidocaine with clonidine, to
that of SGB produced by the injection of lidocaine, alone or combined with clonidine,




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomly assigned to one of three experimental groups”
Comment: method of randomisation not described
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated that study was blinded nor whether participants were
blind to the study hypotheses
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Side effects and effectiveness of treatment were recorded
by another author who was unaware of the procedure”
Comment: while side effects and effectiveness were recorded by a
blinded assessor, the use of self reported outcome in participants
who may not have been blind to the study hypothesis is a possible
risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Excluded 2/45 with clear reasons and clear n reported for all
graphs
Selective reporting (reporting bias) Low risk Adequately reported results for all prespecified outcomes (from
methods section)
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Nascimento 2010 (Continued)
Adequate sample size? High risk n = 45; 15 participants per treatment group
Adequate duration of follow-up? High risk 1 week follow-up
Free of other bias? Low risk No differences between groups for important prognostic factors,
participants not taking any medication at inclusion, outcome
assessment timing identical between groups
Price 1998
Methods Quasi-randomised controlled trial (cross-over)
Participants N = 7 (3 lower extremity, 4 upper extremity pain)
Mean age: 42 years (SD 11; range: 32-52)
Sex: 3 male
CRPS-I or -II of upper or lower extremities (excluded if CRPS in multiple areas)
Diagnostic criteria: IASP (Merskey 1994)
Mean duration of symptoms: 3 years (SD 2 years; range 18 months to 7 years)
Inciting event: trauma (n = 6), surgical (n = 1)
Medico-legal factors: not reported
Previous treatment: not reported
Concomitant treatment: all participants continued concomitant physical therapy and
medications
Interventions Active condition:
SGB with lidocaine (15 ml of lidocaine 1%)
Lumbar sympathetic blockade with 15 ml 1% lidocaine (test solution) followed by 10
ml bupivacaine 0.125%
Evaluation of technical adequacy of block? yes - evaluated Horner’s syndrome and surface
skin temperature for stellate ganglion blocks. Nothing reported for lumbar blocks
Control condition:
Stellate ganglion: 15 ml saline
Lumbar: 15 ml saline + 10 ml saline
The blocks were separated by a period of 7-10 days
Number of blocks: 1 for each condition
Outcomes Pain intensity and pain unpleasantness (0-10 VAS)
Pain outcomes measured every 15 min for 1.5 h prior to injection and every 15 min
for 1 h following injection. Pain outcomes then rated 4 times a day (morning, midday,
afternoon, evening) for 7 days postinjection
Time to peak analgesia measured as the VAS unit difference between pre-injection base-
line pain rating and the lowest VAS rating in the first hour
Duration of pain relief measured as the time it took for pain intensity to return to 50%
of the difference between baseline and peak analgesic effect
Country of origin USA
Study aim To evaluate the diagnostic and therapeutic value of local anaesthetic sympathetic blocks
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Price 1998 (Continued)
Notes Author confirmed the quasi-random allocation in correspondence; adverse events not
reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Four patients received S first with
LA block second, and the order was re-
versed for the remaining 3 patients”
Comment: quasi-random process used, not
truly random. Due to cross-over study de-
sign and successful blinding, we feel this
presents an unclear risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Both the patient and the physician
administering the sympathetic ganglia in-
jections were blind with regard to the con-
tents of the injecting syringe (S or LA) and
with regard to whether skin surface tem-
perature changes or Horner’s syndrome oc-
curred”; “The syringe was filled . . . by a
third person who maintained the code for
the contents of the syringes and the double-
blind nature of the study”; “None of the 7
patients reported subjective differences be-
tween effects of S and LA blocks within the
first hour after block. However, 2 patients
correctly determined that they had received
S injection because of the shorter duration
of relief received.”
Comment: blinding completed and blind-
ing success was formally assessed
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were self rated and participants
were blinded to treatment group
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/7 participants missed all pain unpleasant-
ness data but pain intensity data complete
Selective reporting (reporting bias) High risk Group results for pain unpleasantness
scores not reported
Adequate sample size? High risk N = 7
Adequate duration of follow-up? High risk 7 days follow-up
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Price 1998 (Continued)
Free of other bias? Low risk Quote: “Medication use and physical ther-
apy were as similar as possible for the time
periods following both saline and lidocaine
blocks, and medications were not, as a rule,
significantly adjusted during the study pe-
riod.”
Comment: also, cross-over study design en-
sured similarity between groups for impor-
tant outcomes and outcome assessment at
same time periods
Procedures separated by 7- - 10 days. Fig-
ures illustrate pain returned to baseline lev-
els prior to next block
Rocha 2014
Methods Parallel RCT
Participants N = 36
Mean age (SD):
Group 1 : 42 years (13.5)
Group 2 : 44.4 years (8.9)
Sex: 19 female, 17 male
Upper limb CRPS
Diagnostic criteria: IASP (Merskey 1994) then switched to IASP (Harden 2010). Par-
ticipants screened under old criteria were then excluded
Duration of symptoms (months):
Group 1: 22.7 (26.3)
Group 2: 21.0 (2.16)
Type of initiating injury: mixed: fractures, contusions, surgery, work-related
Concomitant treatments: unclear
Previous treatment: 4 week standardised multimodal protocol including physical ther-
apy, oral analgesic polytherapy: antidepressants, analgesics, opioids, gabapentin and psy-
chological input
Medico-legal factors: not reported
Interventions Group 1: LASB T2 sympathetic ganglion (fluoroscopically guided)
Group 2: subcutaneous space injection of same agents (fluoroscopy also used)
Agents: 10 ml anaesthetic + steroid. 5 ml 75% ropivacaine, 5 ml triamcinolone
Evaluation of technical adequacy of block: yes - measurement of arm temperature
Number of blocks: 1
Outcomes Average pain score from Brief Pain Inventory
McGill Pain Questionnaire
Adverse events
1 month and 1 year follow-up
Country of origin Brazil
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Rocha 2014 (Continued)
Study aim To evaluate the efficacy of TSB for upper limb CRPS-I
Notes Authors declare no conflict of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: no details reported
Allocation concealment (selection bias) Low risk Comment: participants asked to pick an unmarked opaque en-
velope containing allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Personnel not blinded however, comparison is be-
tween two active invasive interventions
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: assessor blinded to intervention
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: 21% attrition at long-term follow-up and imbal-
anced across groups. No details provided regarding reasons for
loss to follow-up
Selective reporting (reporting bias) Low risk Comment: outcomes reporting adequate
Adequate sample size? High risk Comment: N = 36
Adequate duration of follow-up? Low risk Comment: 1-year follow-up
Free of other bias? High risk Comment: average pain scores at baseline differ by more than 1
point
Rodriguez 2005
Methods RCT, parallel design
Participants N= 82
Mean age (no SDs provided):
Group 1: 44.1 years
Group 2: 46.1 years,
Sex:
Group 1: 36.6% male
Group 2: 46.3% male
Upper limb CRPS (type I or type II) with presence of pain mediated by the sympathetic
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Rodriguez 2005 (Continued)
nervous system (defined as a decrease in resting pain by 50% with a stellate ganglion
block)
Diagnostic criteria: IASP (Merskey 1994; Reinders 2002)
Inciting event:
71.4% of CRPS cases were secondary to accidental or violent trauma and 18% occurred
following surgical procedures
Mean duration of symptoms (no SDs provided):
Group 1: 253.7 days
Group 2: 213.4 days
Medico-legal factors:
Group 1: 14.6% had a compensation claim
Group 2: 24.4% had a compensation claim
Previous treatment: participants were excluded if they had previous stellate ganglion
blocks; no other previous treatment reported
Concomitant treatment: Group 1 also received physical therapy and pharmacological
treatment
Interventions Group 1: SGB, physical therapy and pharmacological treatment
Site of block: paratracheal at the height of the cricoid cartilage
Number of blocks: 5
Type of substance injected: 10 cc of volume with equal parts of 2% lidocaine and 0.5%
bupivacaine
Evaluation of technical adequacy: increase in temperature of at least 1° C of the hand
and face (affected side) and the presence of Horner’s syndrome (ptosis of the upper eye
lid and conjunctivitis)
Group 2: Physical therapy and pharmacological treatment only(Control group):
Received physical therapy and pharmacological treatment
Outcomes Pain intensity (VAS). Measured at baseline, 1 month and 2 months. Exact follow-up
time appears to be variable among participants (i.e. followed for more than 2 months in
some)
Therapeuctic efficacy: number of participants with at least 50% reduction in the pain.
Measured at 2 months postintervention
Efficacy: (incidence of pain in control group − incidence of pain in the SGB group)/
incidence of pain in the control group * 100
Absolute risk reduction (incidence of pain in control group − incidence of pain in the
intervention group). Measured at 2 months postintervention
NNTB = 1/ARR (calculated at 2 months postintervention)
Relapse (return of pain to less than 50% reduction or return of pain to baseline levels or
above); determined at 2 months postintervention
Country of origin Colombia
Study aim To determine the analgesic efficacy of the stellate ganglion blockade (SGB) in the alle-
viation of pain mediated by the sympathetic nervous system in patients with Complex
Regional Pain Syndrome
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Rodriguez 2005 (Continued)
Notes This is the first published study by Rodriguez. There are 2 other published studies and
one IASP abstract that use an identical study design. It is unclear if all the studies represent
the same cohort. We attempted to contact the authors 3 times with no success
This study was translated and interpreted by a researcher fluent in Spanish. The study
author, TS, worked with the researcher to fully interpret and score
Funded by Colciencias and the Universidad Libre Seccional Cali. No conflict of interest
stated. No adverse events reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomized”
Comment: method of randomisation unclear
Allocation concealment (selection bias) Low risk Opaque envelopes used; randomly given to each participant
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “double blind”
Comment: Probably not. Index and control groups are not in-
distinguishable, and success of blinding was not tested
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The investigator was reported to be blinded; however, outcomes
were self reported and participants were likely not blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Participants that dropped out or underwent surgery were ex-
cluded from the analysis. The number of excluded participants
per group is not reported
Selective reporting (reporting bias) High risk No pain scores were given and time to relapse was unclear
Adequate sample size? High risk N = 82 (41 in each group)
Adequate duration of follow-up? Low risk Follow-up of 2 months
Free of other bias? Unclear risk No baseline data given on pain intensity; unsure if groups were
similar at baseline
Toshniwal 2012
Methods RCT, parallel design
Participants N= 33
Mean age (SD):
Group 1: 44.33 years (13.6)
Group 2: mean age 42 years (16.6)
Sex:
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Toshniwal 2012 (Continued)
Group 1 (n=19): 6 male
Group 2 (n=14): 7 male
CRPS-I of the upper extremity which had lasted at least 3 months and was refractory to
medical management. People receiving any interventional procedure for the condition
were excluded
Diagnostic criteria: Bruehl 1999 ),
Mean duration of pain (SD):
Group 1: 8.8 months (4.4).
Group 2: 9.3 months (SD 2.8)
Inciting event: not reported
Medico-legal factors: not reported
Previous treatment: not reported
Concomitant treatment: physiotherapy (4 weeks), no change in medication
Interventions Continuous stellate ganglion block (CSG) versus continuous infraclavicular brachial
plexus block (CIBP). Both groups received physiotherapy (as per recommendations from
same physiotherapist) for 4 weeks. No change in regular medications in either group
Group 1: CSG block
Site: stellate ganglion - 20 gauge IV cannula was inserted anterolaterally into the neck,
lateral to the cricoid cartilage. Cannula inserted until the C6 tubercle was hit at which
time the stylet was removed and the cannula vertically sutured to the skin. Cannula
position confirmed via injection of 2 ml of radio-opaque dye under fluoroscopy
Number of blocks: continuous block for 7 days
Type/amount of anaesthetic: bolus of 10 ml (5 + 5 ml) 0.25% bupivacaine was injected.
An elastomeric pump (solution of 0.125% bupivacaine 280 ml, delivering at 2 ml/h)
was attached to the catheter. Pump was changed on day 5
Evaluation of technical adequacy: measured temperature difference between arms (> 1.
5° C temperature increase in the affected arm considered adequate sympatholysis) and
degree of vasodilatation using plethysmography scores (where an increase in the waveform
reading score by 2 was considered improved circulation secondary to sympatholysis/
vasodilatation)
Group 2: CIBP block
Site: brachial plexus - identified using nerve stimulation by vertical approach and inserting
a Contiplex D needle with catheter Position was confirmed via injection of 3 cc of radio-
opaque dye under fluoroscopy
Number of block: continuous block for 7 days
Type/amount of anaesthetic: bolus of 30 ml 0.25% bupivacaine was injected through
the catheter. An elastomeric pump containing 0.125% bupivacaine 400 ml delivering at
5 ml/h was connected to the catheter. Pump was changed on days 3 and 6
Evaluation of technical adequacy: As above. Both groups had an increase in temperature
of the blocked arm (vs contralateral hand) and improvement in circulation (at 30 min);
no difference between groups
Outcomes Neuropathic pain scale - components analysed separately (intensity, sharp, hot, dull,
cold, sensitive, itchy, unpleasant, deep pain, surface pain, and quality of pain). Scale was
0 (i.e., intensity, 0 = no pain) to 10 (i.e., intensity, 10 = most intense pain sensation
imaginable)
Measured at 6 min, 30 min, 2 h, 12 h, and 24 h, day 2, day 3, day 4, day 5, day 6, day
7, week 2, week 3, week 4
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Toshniwal 2012 (Continued)
Adverse events reported
Country of origin USA
Study aim To compare the efficacy of continuous stellate ganglion (CSG) block with that of con-
tinuous infraclavicular brachial plexus (CIBP) block in management of CRPS type I of
upper extremity
Notes The authors acknowledged editorial support from 2 doctors from Wayne State University,
Detroit. The authors declared that they have nothing to disclose and no conflict of
interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “patients . . . were randomly assigned to receive CSG
block or CIBP block using a computer-generated table of ran-
dom numbers (50 numbers in two columns)”
Comment: likely done
Allocation concealment (selection bias) Low risk Quote: “Group allocation was concealed in sealed opaque en-
velopes that were not opened until patient consent had been
obtained”
Comment: likely done
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Both active interventions but does not mention blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcomes are self rated, thus unclear risk due to uncertainty
whether participants were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Three patients were dropped from the study. One pa-
tient from each group was excluded from the study as their
catheters became dislodged during the follow-up period, and
one patient in the CIBP group was excluded because he failed
to follow up after 2 weeks”
Comment: drop-out rates < 20% (1 group had 1/19 drop out
(5.3%) and 1 had 2/14 drop out (14.3%)). Similar reasons for
drop-out
Selective reporting (reporting bias) Low risk Reports all outcomes and all between-group differences
Adequate sample size? High risk n = 18 (CSG), n = 12 (CIBP)
Adequate duration of follow-up? Unclear risk 4 weeks of follow-up
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Toshniwal 2012 (Continued)
Free of other bias? Low risk Groups were similar on important prognostic factors
Yoo 2012
Methods Parallel RCT
Participants N = 42
Mean age (SD):
Group 1: 61.3 years (5.6)
Group 2: 59.1 years (4.5)
Sex: 25 males, 20 females (note: likely error as not consistent with overall N)
CRPS poststroke, upper limb
Type of initiating injury: stroke
Diagnostic criteria: IASP Harden 2010
Duration of symptoms - “duration since stroke”.
Group 1: 2.8 months (1.1)
Group 2: 2.3 months (0.9)
Previous treatment: not reported
Concomitant treatments: not reported
Medico-legal factors: not reported
Interventions Group 1: stellate ganglion block without ultrasound guidance. 10 ml lidocaine injection
Group 2: stellate ganglion block with ultrasound guidance. 5 ml lidocaine injection
Number of blocks: 2, 1 week apart
Evaluation of technical adequacy of block: none
Outcomes Pain intensity VAS, 0-10, anchors “no pain” and “the highest pain”
2- and 4-week follow-up
Adverse events
Country of origin Korea
Study aim To evaluate the effectiveness of ultrasound-guided SGB by comparing with the blind
SGB in poststroke CRPS patients in reducing pain and swelling of the affected limb
Notes Conflict of interest not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: method of randomisation not reported
Allocation concealment (selection bias) Unclear risk Comment: allocation concealment not reported
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Yoo 2012 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Participant blinding not reported. The interventions
are likely to be distinguishable, however both were active invasive
interventions
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: blinding of participants is unclear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: there are anomalies between group numbers in the
text and table 1
Selective reporting (reporting bias) Low risk Comment: outcome reporting adequate
Adequate sample size? High risk Comment: N = 42
Adequate duration of follow-up? Unclear risk Comment: follow-up stated at 4 weeks
Free of other bias? Unclear risk Comment: no information given on concomitant treatment
Zeng 2003
Methods RCT, parallel
Participants N = 60
Age range: 38-71
Sex: 42 males
Shoulder-hand syndrome following stroke
Diagnostic criteria not reported
Duration of symptoms; described as “in the early stages of SHS complicated with paral-
ysis”
Previous treatment not specified
Mean baseline pain, 0-10 VRS (SD):
SGB + rehab group: 6.95 (3.24)
Rehab-only group: 6.85 (3.24)
Medico-legal factors: not reported
Concomitant treatments: not reported
Interventions Stellate ganglion block + rehabilitation versus rehabilitation only
SGB: anterior entry, transverse process of C7, agent, dose not reported
Rehabiliation details: reports “comprehensive treatment” eliminating causes of oedema,
avoid weight loading of limb, avoid limb trauma, remove factors causing shoulder pain,
movement exercises, joint mobilisations, ice therapy, physical therapy
Outcomes Pain VAS (0 = no pain, 2 = little pain, 4 = frequent mild pain or occasional severe pain,
6 = severe pain but tolerable, 8 = continuous pain and intolerable, 10 = severe pain that
couldn’t be touched)
Pain was measured before treatment, at 10 days and 20 days post-treatment
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Zeng 2003 (Continued)
Country of origin China
Study aim Effect of stellate ganglion is observed on base of comprehensive rehabilitation treatment
(sic)
Notes No statement of financial support or conflict of interest; adverse events not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomly divided into two groups”
Comment: method of randomisation not reported
Allocation concealment (selection bias) Unclear risk Allocation concealment not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Index and control groups are not indistinguishable and success
of blinding was not tested
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Participant-rated outcomes; participants not blinded (as above)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs
Selective reporting (reporting bias) Low risk All prespecified outcomes adequately reported on
Adequate sample size? High risk N = 60 (30 in each group)
Adequate duration of follow-up? Unclear risk 20 days follow-up
Free of other bias? Low risk Quote: “All patients were in early stage of SHS complicated
with paralysis”; “there weren’t statistical differences at age, sex,
rehabilitation kind”
Comments: no difference between groups in age, sex, rehabili-
tation and duration of symptoms; outcome assessment timing
identical
ARR: absolute risk reduction; BTA: botulinum toxin A; CIBP: continuous infraclavicular brachial plexus block; CRPS: complex regional
pain syndrome; CSG: continuous stellate ganglion block; IASP: International Association for the Study of Pain;IV: intravenous;
IVRB: intravenous regional blockade; LASB: local anaesthetic sympathetic blockade; NNTB: number needed to treat for an
additional beneficial outcome; PRF: pulsed radiofrequency; RCT: randomised controlled trial; RSD: reflex sympathetic dystrophy;
SD: standard deviation; SE: standard error; SF-36: 36-item short-form health survey; SGB: stellate ganglion blockade; SMP:
sympathetically maintained pain; VAS: visual analogue scale; VRS: verbal report scale.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ackerman 2006 Not randomised
Arias 1989 Not randomised
Catala 1994 Sympathetic blockade versus intravenous lidocaine for postherpetic neuralgia
Dellemijn 1994 Sympathetic blockade versus phentolamine infusion
Erickson 1993 Not randomised
Farcot 1990 Not randomised
Fukusaki 1995 Nerve blocks (including sympathetic blocks) for cervical radiculopathy
Garrido 2005 Not randomised
Glynn 1993 Not randomised
Hartrick 2004 Not randomised
ISRCTN71968956 Not randomised
Kastler 2013 Not randomised
Linson 1983 Not randomised
Malmqvist 1992 Not randomised
Meier 2009 < 48 h follow-up postblock
Perrigot 1982 Not a local sympathetic block
Quevedo 2005 Not randomised
Raja 1991 < 48 h follow-up postblock
Schurmann 2001 Not randomised
Steinbrocker 1953 Not randomised
Tran 2000 Sympathetic blockade plus iohexol versus sympathetic blockade plus saline; evaluating the effect of the contrast
agent iohexol
Verdugo 1995 <48 h follow-up postblock
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(Continued)
Wang 1985 Not randomised
Wehnert 2002 <48 h follow-up postblock
Yucel 2009 Not randomised
Characteristics of studies awaiting assessment [ordered by study ID]
Kostadinova 2012
Methods Parallel RCT
Participants N = 32
Interventions Stellate ganglion block with bupivacaine vs bupivocaine plus neostigmine
Outcomes Not reported
Notes Abstract of protocol only available - authors contacted for further details
Rodriguez 2006
Methods Parellel RCT
Participants N = 71
Interventions SGB, physical therapy and pharmacological treatment vs physical therapy and pharmacological treatment
Outcomes Pain intensity VAS 10 cm. Proportion with 50% pain relief 1 month postblock
Notes Not clear whether a distinct trial or an extension of Rodriguez 2005. Authors contacted for clarification.
Rodriguez 2008
Methods Parellel RCT
Participants N = 114
Interventions SGB, physical therapy and pharmacological treatment vs physical therapy and pharmacological treatment
Outcomes Pain intensity VAS 10 cm. Time to relapsing. 6-month follow-up
Notes Conference abstract. Not clear whether a distinct trial or an extension of Rodriguez 2005. Authors contacted for
clarification.
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Salinas Cerda 1997





RCT: randomised controlled trial; SGB: stellate ganglion blockade; VAS: visual analogue scale.
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Budapest criteria: diagnostic criteria for complex regional pain syndrome
To make the clinical diagnosis, the following criteria must be met:
1. Continuing pain, which is disproportionate to any inciting event
2. Must report at least one symptom in three of the four following categories.
• Sensory: reports of hyperaesthesia, allodynia, or both.
• Vasomotor: reports of temperature asymmetry, skin colour changes, skin colour asymmetry, or a combination of these.
• Sudomotor/oedema: reports of oedema, sweating changes, sweating asymmetry, or a combination of these.
• Motor/trophic: reports of decreased range of motion, motor dysfunction (weakness, tremor, dystonia), trophic change (hair,
nail, skin), or a combination of these.
3. Must display at least one sign at time of evaluation in two or more of the following categories:
• Sensory: evidence of hyperalgesia (to pinprick), allodynia (to light touch, temperature sensation, deep somatic pressure, or
joint movement), or both
• Vasomotor: evidence of temperature asymmetry (> 1° C), skin colour changes, asymmetry, or a combination of these.
• Sudomotor/oedema: evidence of oedema, sweating changes, sweating asymmetry, or a combination of these.
• Motor/t rophic: evidence of decreased range of motion, motor dysfunction (weakness, tremor, dystonia), trophic changes
(hair, nail, skin), or a combination of these.
4. There is no other diagnosis that better explains the signs and symptoms
For research purposes, diagnostic decision rule should be at least one symptom in all four symptom categories and at least one sign
(observed at evaluation) in two or more sign categories. A sign is counted only if it is observed at time of diagnosis.
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Complex Regional Pain Syndromes] explode all trees
#2 complex regional pain syndrome
#3 reflex sympathetic dystrophy
#4 reflex neurovascular dystrophy
#5 (RSD or RND)





#11 (sympathetic* near/3 pain*)
#12 SMP
#13 ((posttraumatic or post-traumatic) next dystrophy)
#14 neuralgia
#15 MeSH descriptor: [Neuralgia] explode all trees
#16 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15
#17 MeSH descriptor: [Sympatholytics] explode all trees
#18 MeSH descriptor: [Nerve Block] explode all trees




#23 (nerve* near/5 block*)
#24 (stellate near/5 block*)
#25 (sympathetic* near/5 block*)
#26 sympatholytic*
#27 (local near/5 (anaesthetic* or anesthetic*))
#28 #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27
#29 #16 and #28
Appendix 2. MEDLINE search strategy
1 exp Complex Regional Pain Syndromes/
2 complex regional pain syndrome.mp.
3 CRPS.mp.
4 reflex sympathetic dystrophy.mp.
5 reflex neurovascular dystrophy.mp.
6 (RSD or RND).mp.





12 (sympathetic* adj3 pain*).mp.
13 SMP.mp.
14 ((posttraumatic or post-traumatic) adj dystrophy).mp.
15 neuralgia.mp. or exp Neuralgia/
16 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15
17 exp Sympatholytics/
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18 exp Nerve Block/




23 (nerve* adj5 block*).mp.
24 (stellate adj5 block*).mp.
25 (sympathetic* adj5 block*).mp.
26 sympatholytic*.mp.
27 (local adj5 (anaesthetic* or anesthetic*)).mp.
28 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27
29 16 and 28
30 randomized controlled trial.pt.







38 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37
39 29 and 38
Appendix 3. EMBASE search strategy
1 exp Complex Regional Pain Syndromes/
2 complex regional pain syndrome.mp.
3 CRPS.mp.
4 reflex sympathetic dystrophy.mp.
5 reflex neurovascular dystrophy.mp.
6 (RSD or RND).mp.





12 (sympathetic* adj3 pain*).mp.
13 SMP.mp.
14 ((posttraumatic or post-traumatic) adj dystrophy).mp.
15 neuralgia.mp. or exp Neuralgia/
16 or/1-15
17 exp Sympatholytics/
18 exp Nerve Block/




23 (nerve* adj5 block*).mp.
24 (stellate adj5 block*).mp.
25 (sympathetic* adj5 block*).mp.
26 sympatholytic*.mp.
27 (local adj5 (anaesthetic* or anesthetic*)).mp.
52Local anaesthetic sympathetic blockade for complex regional pain syndrome (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
28 or/17-27







36 (doubl$ adj blind$).tw.






43 Randomized Controlled Trial/
44 Single Blind Procedure/
45 or/30-44
46 (animal/ or nonhuman/) not human/
47 45 not 46
48 29 and 47
Appendix 4. LILACS search strategy
“complex regional pain syndrome” or CRPS or “reflex sympathetic dystrophy” or “reflex neurovascular dystrophy” or RSD or RND
or “shoulder hand syndrome” or algoneurodystrophy or algodystrophy or sudeck$ or causalgia or sympathetic pain$ or SMP [Words]
and bupivacaine or lidocaine or guanethidine or (nerve$ block$) or (stellate block$) or (sympathetic$ block$) or sympatholytic$ or
(local anaesthetic$) or (local anesthetic$) [Words]









































X X - X - Very low
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Lim 2007 38 No differ-
ence





















X X - X - Very low
LASB+ vs
PT
Zeng 2003 60 No differ-
ence












- X - X - Low
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Yoo 2012 42 No differ-
ence
X X X X - Very low
X = downgrade on this criteria; BTA: botulinum toxin A; IVRB: intravenous regional blockade; LASB: local anaesthetic sympathetic
blockade; PT: physical therapy; SGB: stellate ganglion blockades.
W H A T ’ S N E W
Last assessed as up-to-date: 16 September 2015.
Date Event Description
28 July 2016 Review declared as stable See Published notes.
H I S T O R Y
Protocol first published: Issue 1, 2004
Review first published: Issue 4, 2005
Date Event Description
7 March 2016 New citation required but conclusions have not
changed
The conclusions of the review remain unchanged.
16 October 2015 New search has been performed This updated review used refined exclusion crite-
ria (exclude studies with follow-up of <48hrs) (see
Differences between protocol and review). This re-
sulted in the exclusion of 4 studies from this update
that had been included in previous versions of this re-
view (Meier 2009; Raja 1991; Verdugo 1995; Wehnert
2002). We also updated the data analysis that included
consideration of the minimally important difference
(as per OMERACT 12 group recommendations) and
evaluation of the quality of evidence using the GRADE
approach
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(Continued)
26 June 2013 New search has been performed This updated review used an expanded search strategy,
updated Risk of Bias assessment, and updated inclu-
sion criteria. These changes resulted in inclusion of
10 additional studies compared with the initial review
(n = 363 additional participants); two studies com-
pared LASB to a placebo/inert treatment (Aydemir
2006; Price 1998), the remaining nine studies com-
pared LASB with an active treatment [Bonelli 1983;
Carroll 2009; Meier 2009; Nascimento 2010; Raja
1991; Toshniwal 2012; Wehnert 2002; Zeng 2003)
or investigated the effect of adding LASB to an active
treatment (Rodriguez 2005). Despite these method-
ological updates and inclusion of new studies, the con-
clusions of the review remain unchanged; there is a
dearth of published evidence for LASB and the avail-
able evidence suggests lack of efficacy. Readers of the
original review would benefit from reading this update
as new evidence is provided for treatment comparisons
between LASB and other active interventions (for ex-
ample, intravenous regional anesthesia)
26 June 2013 New citation required but conclusions have not
changed
Despite methodological updates and inclusion of new
studies, the conclusions of the review remain un-
changed; there is a dearth of published evidence for
LASB and the available evidence suggests lack of effi-
cacy
3 October 2011 Amended The following changes have been made to the method-
ology of the protocol. We have made them all to bring
the protocol up to date with the current PaPaS author
guidelines:
We have chosen to adopt a modified version of the
Cochrane ROB tool with additional criteria added
in response to the recommendations of Moore et al.
(2010). As such we have added 2 additional criteria
“Size” and “Duration” using the thresholds for judge-
ment suggested by Moore 2010. We have not added
the “Outcome” criteria as this is covered already by
our choice of primary outcome measures
We have rewritten the data synthesis/ analysis sections
to fit the current RevMan headings. We now specify
that we will calculate Risk Ratio for achieving a mod-
erately important benefit (30% or more) or a substan-
tially important benefit (50% or more) and have spec-
ified time windows for short, medium and long term
follow up. We suggest the following preplanned sub-
group analyses where adequate data allow: CRPS I vs
II, Adults vs children and single vs continuous block-
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(Continued)
ade
We have added a planned sensitivity analyses, where
data are sufficient, to allow testing of the effect of in-
cluding/ excluding studies whose risk of bias is unclear
or high
3 October 2011 Amended The Background section has been substantively rewrit-
ten to fit the headings now suggested in RevMan
22 September 2011 Amended Searching other resources - unpublished studies: We
have expanded this search strategy to also include clin-
ical and controlled trial registers, such as http://www.
controlledtrials.com/, the Australian New Zealand
Clinical Trials Register (http://www.anzctr.org.au/)
, and a European Clinical Trials Register (https://
www.clinicaltrialsregister.eu/).
21 September 2011 Amended We have added new search terms to the search strat-
egy that will make it more sensitive and conforms to
updates in treatment (for example, Botox now being
used for sympathetic chain blockades). Also attached
is an updated search strategy for Medline, created in
collaboration with Jane Hayes from PaPaS
21 September 2011 Amended Methods: selection of studies. Two independent re-
viewers will screen the titles and abstracts of the search
results in order to determine which full text articles to
retrieve. This is changed from one reviewer
21 September 2011 Amended Addition of new criteria for considering studies for this
review (Types of interventions)
21 September 2011 Amended We have inserted a new Table (under other Tables)
that provides the new Budapest criteria for diagnosing
CRPS
21 September 2011 Amended Addition of new criteria for considering studies for this
review (Types of participants)
9 November 2009 Amended Contact details updated.
30 October 2008 Amended Converted to new review format.
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C O N T R I B U T I O N S O F A U T H O R S
NEO: informed the modification of the protocol; acted as the arbiter reviewer; led the data synthesis and the writing of the manuscript.
BMW: informed the modification of the protocol; screened, identified and evaluated studies; extracted data; and contributed to the
writing of the manuscript.
WG: informed the modification of the protocol; screened, identified and evaluated studies; extracted data; and contributed to the
writing of the manuscript
DBC: designed the original protocol and consulted on the modifications; contributed to the writing of the manuscript.
FB: informed the modification of the protocol; assisted in the clinical trial register searches; and contributed to the writing of the
manuscript.
TRS: led the modification and writing of the protocol; performed the literature search; screened, identified and evaluated studies;
extracted data; informed the data synthesis; and informed the writing of the manuscript.




DBC: none known; DBC practiced anesthesiology and pain medicine in busy academic medical centers from 1986-2005, directly
treating patients with CRPS, but has not treated people with CRPS since 2005.
FB: none known; FB is a practicing neurologist and pain treatment specialist who treats patients with CRPS.
TRS: none known.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• Saltonstall Foundation, USA.
• Javeriana University School of Medicine, Colombia.
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D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
This 2016 updated review used an expanded search strategy. In particular, we used additional search terms and also searched clinical
trial registers for potentially relevant studies. For this update, we excluded studies that had only immediate follow-up data (≤ 48 h),
because this information provides little clinically relevant information about the clinical effectiveness of this treatment.
Further, we used an updated version of the ’Risk of bias’ assessment - specifically, we included ’size of treatment groups’ and ’duration
of follow-up’ in the ’Risk of bias’ evaluation. This updated review also included studies comparing local anaesthetic blockade (LASB)
versus other active treatments (original review compared LASB with placebo/inert treatments only). Lastly, we updated the data analysis
that included consideration of the minimally important difference (as per OMERACT 12 group recommendations) and evaluation of
the level of evidence using the GRADE approach.
N O T E S
A new search within two years is not likely to identify any potentially relevant studies likely to change the conclusions. Therefore, this
review has now been stabilised following discussion with the authors and editors. The review will be re-assessed for updating in five
years. If appropriate, we will update the review before this date if new evidence likely to change the conclusions is published, or if
standards change substantially which necessitate major revisions.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Anesthetics, Local; Autonomic Nerve Block [∗methods]; Causalgia [drug therapy]; Complex Regional Pain Syndromes [∗drug therapy];
Randomized Controlled Trials as Topic; Reflex Sympathetic Dystrophy [drug therapy]
MeSH check words
Adult; Child; Humans
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